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Abstract
Opioid abuse costs affect the majority of the adult population in our society directly or
indirectly. The current prevailing medical treatment for opioid addiction is methadone
maintenance treatment (MMT). MMT reduces infectious disease spread, illicit drug use,
criminal activity, and overdose potential. MMT is only as effective as the length of time a
client remains active and compliant with the program. In previous studies, therapeutic
alliance (TA) has been shown to positively influence the effectiveness of substance abuse
treatment. However, a gap exists in research in regards to the impact of TA on the
effectiveness of MMT outcomes. The theoretical framework of this study is based on
therapeutic alliance, which guided an examination on whether therapeutic alliance (as
measured by the Session Rating Scale) influenced MMT retention and compliance (drug
screens and session attendance). Archival data from 264 clients receiving MMT for
opioid dependence were reviewed from a nonprofit community-based agency in Arizona.
Logistic regression results revealed that TA did not significantly affect retention or
compliance. However, issues were noted such as how the SRS was administered, a lack
of understanding by clients regarding scoring the SRS, and unique social desirability
demands when clients are in MMT. The finding that TA alone did not significantly affect
retention and compliance does not decrease the need to find effective means to improve
MMT outcomes. Rather, the findings suggest a critical need to identify and utilize
measures more appropriate for clients receiving MMT. In doing so, positive social
change may be achieved by assisting clinical staff in developing a strong therapeutic
alliance with MMT clients as they focus on problem solving as a joint venture when
challenges in the recovery process arise.
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Chapter 1: Introduction to the Study
Background
With numerous cutbacks in Medicaid funding, and rising health care costs, it is
beneficial to examine potential cost factors in various areas of treatment and determine means
to reduce those costs. In this study, I focused on treatment for opioid dependence. The negative
stigma surrounding methadone maintenance treatment may often bring this form of treatment
into scrutiny. Opioid abuse costs are a burden on the United States (Ghate, Harooutiunian,
Winslow, & McAdam-Marx, 2010). Opioid abuse related costs have increased in several areas;
medical associated costs, criminal activity costs and emotional costs to families of the
substance abuser (White et al., 2005; SAMHSA, 2013; Birnbaum, Reynolds, Jetley, Zhang, &
Vallow, 2004). White et al, (2005) pointed out that in the 2-year period from 1999 to 2001
admissions for treatment of prescription opioids increased by 15,000 and from the prior
reported two-year period of 1999 to 2001, and emergency room visits related to illegal or
nonmedical use of prescription drugs increased by 75,000 incidents. SAMHSA (2013) reported
that the number of individuals in 2012 with heroin dependence or abuse (467,000) was close
to double that of 10 years earlier (214,000). The Centers for Disease Control and Prevention
(CDC), (2002) reported that over one third of AIDS cases have been directly and indirectly
related to injection drug use. Birnbaum et al. (2004) determined that prescription opioid abuse
costs in 2001 were $9.2 billion. The National Institute of Drug Abuse (2013) reported that in
2011, approximately 4.2 million Americans age 12 years or older had used heroin at least once
in their lives and approximately 23% of those individuals who use heroin become dependent
on it. Paulozzi (2006) reported that from 1997 to 2002 the number of heroin, cocaine, and
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opioid analgesic deaths increased 28.7 % to 10,727, with a reported increase of 96.6% in opioid
analgesics. Opioid abuse includes not only heroin, but abuse of prescription pain medications
such as Codeine, Morphine, Diluadid, Oxycontin/Oxycodone and others. The Centers for
Disease Control (CDC; 2012) has identified prescription drug use (opioid based pain
medications and benzodiazepines) as the fastest growing drug problem in the United States;
pain pills are included in the class of opioids that are abused. The CDC also identified that
there are approximately 9 million individuals who are prescribed and have long-term medical
use of opioids and approximately 5 million individuals who report illegal use of opioid
analgesics in the past month. The financial and emotional costs of opioid addiction are a burden
on society.
Methadone is a synthetic narcotic analgesic used for treatment of people addicted to
opioids. Methadone is also used for other medical purposes such as treatment of pain but for
the purpose of this research the focus is purely on the treatment of opioid addiction. The
purpose of methadone is to keep the individual from experiencing withdrawal symptoms and
control the cravings for illicit use, and when the dose is sufficiently high enough, it produces
blocking of the effects of illicit opioid drugs. The purpose of methadone maintenance therapy
(MMT) in opioid addiction is to reduce withdraw symptoms from opioids, prevent infectious
disease spread, prevent illicit drug use, prevent criminal activity associated with drug use,
and decrease overdose potential and interpersonal difficulties (Ward, Hall, & Mattick, 1999;
Reisinger et al., 2009; Krambeer, Von McKnelly, Gabrielli, & Penick, 2001). Since the
1960s, MMT has been shown an effective treatment for improving quality of life for opioiddependent individuals and society. MMT has contributed to reduced death rates related to
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overdoses, reduced criminal behavior related to drug seeking or use, and reduced spread of
diseases related to intravenous needle. Methadone can be effective to assist in stabilizing an
individual so that attention can be given to other areas such as medical and mental health and
in the long-term maintenance until an individual is ready for detoxification (Krambeer et al.,
2001 ). Safe, proper use of methadone does continue opioid dependency but offers freedom
from compulsive and disruptive behavior associated with heroin addiction. However, there is
a gap in the literature with regard to factors that are most cost effective and are significantly
related to retention and compliance for those involved in MMT. In this exploratory study, I
intended to offer an understanding of the effects of TA on MMT compliance and retention to
improve the effectiveness through improving TA, with the goal of keeping the cost factors of
improvement low.
Studies Addressing the Problem
Kayman, Goldstein, Deren, and Rosenblum (2006) identified that length of time
engaged in substance abuse treatment is associated with improved quality of life outcomes,
and those individuals that do not complete treatment are at high risk. Kayman et al. (2006)
described success with MMT as requiring the individual to stabilize in areas such as a
returning to a normalized brain functioning level, ability to control triggers, urges and
stabilization in their environment (e.g., employment, housing, social and family
relationships). Magura, Nwakeze, and Demsky (1998) conducted a study with 3,248 patients
and found the length of treatment was in direct proportion to decreased daily opioid use and
decreased criminal behavior. Ball, Lange, Myers, and Friedman (1988) identified that of
clients that left treatment programs prematurely that 82% relapsed to intravenous (IV) use
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shortly after discharge. Drug treatment studies have shown that retention is a major factor in
treatment outcomes and treatment dropout has been an issue (Gossop, Stewart, Browne, &
Marsden, 2002; Reisinger et al. 2009; Simpson & Sells, 1982). Clausen, Waal, Thoresen, and
Gossop (2009) found that older users were at higher risks for mortality due to over-dose
(OD) when MMT ceased. Hubbard, Craddock, and Anderson (2003) and Gossop, Trakada,
Steward, and Witton (2005) found in their 5-year follow-up studies of outcomes for those
with drug abuse treatment completion that there were substantial reductions in criminal
activity. Hubbard et al. also found higher reported rates of full-time employment by those
with treatment lengths over 6 months. Ball et al. (1988) conducted a study on six methadone
programs and found that a reduction from 100% to 29% in IV drug use in clients active in the
methadone program 4 years after initial admission. Research suggests that treatment
compliance the first 12 months of MMT is critical to client outcomes (Simpson, Joe &
Brown, 1997; Simpson, D., Joe, G. & Rowan-Szal, G., 1997). Simpson (1981) found that
time in treatment is a strong indicator of treatment outcomes.
Several variables have been researched in relation to MMT treatment retention.
Sociodemographic predictors for retention include age at admission, keeping good
relationship with family, source of income, employment, education, marital status, living in
rural area, and involvement in the criminal justice system (Magura et al., 1998; Yang et al.,
2013; Zhang et al., 2013). In a retrospective longitudinal study with 2,728 clients enrolled
across 56 MMT clinics in Guangdong, China, through 2010, Yang et al. (2013) found that
statistically significant predictors of retention included the following: age at admission being
older than 30 years old, keeping good relationship with family, source of income, the daily
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cost of drug use preadmission, living in rural area, sharing needles, and history of being
arrested. Magura et al. (1998) conducted a study among 2,454 patients admitted to the 15
clinics throughout New York City found that criminal arrests during MMT significantly
affected retention outcomes. Huissoud, Rousson, and Dubois-Arber’s (2012) results agreed
with other studies and found age under 30 as a significant factor predicting MMT treatment
dropout. Another finding of the study is related to race identification: African American
clients were not as likely to remain in MMT in comparison with Caucasian or Hispanic
clients (Magura et al., 1998). The influence of being African American and experiencing
significant dropout rates was further supported by Mancino et al. (2010) and Saxon, Wells,
Fleming, Jackson, Calsyn (1996).
The effect of dosing levels with regard to MMT program retention has been studied
extensively, and findings have agreed that higher doses encourages retention and lower illicit
drug use (Joe, Simpson, & Sells, 1994; Yan-ping et al., 2009; Mohamad, Abu Bakar, Musa,
Talib, & Ismail, 2010; Salamina et al., 2010) There has been so much attention and research
given in the area of effective dosing and prediction of treatment retention that it is
unreasonable to give an adequate representation or summary. The overall consensus is that
higher dosing is a significant factor in MMT treatment retention; however, there does not
appear to be a consensus on what the higher dose limits are.
Psychosocial treatment is another variable that has been researched in relation to
effectiveness in MMT programs. Salamina et al. (2010) found that regardless of the type of
psychotherapy conducted, clients receiving psychotherapy were almost twice as likely to be
retained in MMT (315 days with psychotherapy vs. 167 days without psychotherapy).
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Magura, Rosenblum, Fong, Villano, and Richman (2002) found that in a study of two clinics
with cocaine-using methadone patients who were assigned to enhanced methadone treatment,
primarily cognitive-behavioral therapy (CBT) in comparison with similar patients in two
other clinics who received standard methadone treatment without CBT, the treatment
condition of CBT did not significantly affect outcome. Magura et al. (2002) reported that
those clients receiving CBT relayed higher reports of TA and obtained more supportive
services than those receiving standard treatment.
Insufficient research has been conducted on TA related to retention and outcomes.
Palmer, Murphy, Piselli, and Ball (2009) found that poor staff connection (therapeutic
alliance) issues are one of the factors identified as contributing to dropout from substance
abuse treatment. Joe, Flynn, Broome, and Simpson (2007) stated that a clients’ progress is
measured by the clients’ pattern of drug use and treatment engagement, as well as their
alliance with his or her counselor. Kelly, O’Grady, Brown, and Michell (2010) found that
clients’ that reported they were satisfied with their clinical staff and the program were more
likely to be retained in MMT at 12 months. Joe et al. (2001) and Meir, Barrowclough, and
Donmall (2005) found that the counseling rapport reported by clients was a predictor of
treatment outcomes and in part for treatment retention. The study found higher rates of
reported rapport when the client believed they were being supported as opposed to peer
confrontational or punitive means of treatment.
Problem Statement
Despite the successful use of longer-term methadone maintenance treatment,
problems remain. Sees et al. (2000) and Paulozzi (2006) noted an increase in deaths related
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to oxycodone and methadone in urban areas between 1997 and 2002. Modesto-Lowe,
Brooks, and Petry (2010) relate higher risk factors in MMT with the fact that clients using
MMT are young, exhibit antisocial traits and thus are more prone to misusing methadone or
to use multiple substances. The results of their study suggested that by nature that clients of
MMT are at risk for low treatment compliance such as lower adherence to attendance to
scheduled sessions, illicit drug use, and leaving treatment early, which often leads back to
opioid relapse and return to other undesirable behaviors such as crime.
Defining the minimal amount of service needed to ensure higher rates of successful
outcomes is important because as Kraft, Rothbard, Hadley, McLellan, and Asch (1997)
pointed out, literature states a combination of services such as employment, housing, and
medical care services are necessary for drug-addicted clients to obtain recovery but,
unfortunately owing to the costs of these services, they are limited in most methadone
treatment. The costs of additional services such as day treatment offer no significant
difference in outcomes in comparison to individuals that receive services of significantly less
costs such as enhanced MMT services (Avants et al., 1999). Determining the necessary cost
effective factors that lead to retention and positive outcomes needs to be considered
especially with today’s economic budget constraints.
Condelli and Dunteman (1993) conducted a study that found of 526 clients admitted
into 17 methadone programs in the course of a 2-year period, retention was highest in
programs that kept clients apprised of their dose, were accessible, and offered quality case
management services. Kelly et al. (2010) found that clients who reported program
satisfaction remained with the program for a minimum of 12 months. The definition of
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quality services and what it is composed of is a question that is often undefined, but it may be
reasonable in reviewing the research to include TA as one measurement of quality service.
The quality of the relationship between the client and the counselor affects retention
and compliance in drug treatment and may be a component of quality service. If a client is
reporting satisfaction with their program, he or she may also have some form of a positive
TA with his or her clinical staff. Meir, Donmall, McElduff, Barrowclough, and Heller (2006)
found that clients who reported a weak TA with their counselor dropped out of drug
treatment significantly earlier than those clients who reported a stronger therapeutic alliance.
There appears to a problem with how TA is defined. There is no one operational
definition of TA, and the variation in how the clinical staff defines it and how the clients
identified it may differ. Krause et al. (2011) identified that clients may have an emotional
bond expectation (that the therapist should be gentle, accepting, nonaggressive,
nonjudgmental, warm, and empathic) for their definition of TA, whereas clinical staff may
not value an emotional bond as part of TA. Other factors that Krause et al. stated that the
client acknowledged as part of TA is that they felt acceptance by their therapist, that the
client trusted the therapist and vice versa, and that the client felt understood. Krause et al.
concluded “that the alliance is an emergent quality of working together productively within
an asymmetric relationship” (p. 279). Common descriptions of TA appear to include the
ability of the therapist and client to work together on common tasks and goals and the
affective nature of the relationship (Bordin, 1979; Horvath & Symonds, 1991; Saunders,
Howard, & Orlinsky, 1989).
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With most states cutting funding for mental health and substance abuse, program
funding must distributed among those with the greatest potential of recovery and the highest
effect on community improvement (e.g., reduction in crime, reduced dependence on
governmental funding). Finding the link between improving the effectiveness of MMT and
reducing costs to society will assist in continuation of this treatment modality.
Improving TA may improve the likelihood that clients stay compliant with
methadone treatment requirement by being retained longer in treatment. Developing alliance
does not increase program costs as significantly as developing social supports because
developing therapeutic alliance can be taught through in-service trainings or other means.
Therapeutic alliance may improve retention and compliance in a cost-effective and efficient
manner, as opposed to buying new group materials, training different therapeutic approaches,
or developing social support programs. Duncan and Miller (2008) pointed out that the
therapist’s ability to build TA with the client accounts for 6% to 9% of the change in clients
as opposed to the model or technique used (1%) but therapist effectiveness may range from
twenty to seventy percent.
I intended to examine whether client-reported level of TA was associated with
improved outcomes, as defined by retention and compliance (attendance to scheduled
group/individual sessions and drug screenings). I hypothesized that high levels of reported
TA by clients would result in longer length of stay (retention) and higher levels of
compliance (less positive drug screenings and higher rates of attendance to scheduled
sessions).
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Nature of the Study
I attempted to determine whether higher levels of reported TA predicted MMT
retention and compliance. Initially, the differences between participants receiving methadone
maintenance treatment for opioid dependence reporting positive TA and participants
reporting negative TA were analyzed against MMT retention. Further examination included
reviewing the differences between participants receiving methadone maintenance treatment
for opioid dependence reporting positive therapeutic alliance (Session Rating Scale score >
36) and participants reporting negative therapeutic alliance (Session Rating Score < 36)
against compliance measured by number of positive drug screenings and attendance to
scheduled individual/group sessions. Therefore, I also attempted to determine whether higher
levels of reported TA can predict MMT program compliance as measured by less positive
drug screenings and higher attendance to scheduled sessions.
The participants were sorted and randomly selected from a database of clients that
had a history of receiving outpatient MMT from one of the four MMT clinics operated by the
agency used for this study, which was located in Arizona. The agency is a not-for-profit
agency, and clients were evaluated from 2010 to 2014. The hypothesized independent
variable was defined as reporting of positive or negative therapeutic alliance (Session Rating
Scale scores +/- 36), and the dependent variables were defined as treatment retention at or >
1 year, and treatment compliance described as number of positive drug screens while in
treatment and attendance to scheduled appointments for individual/group sessions.
The study was a quantitative cross-sectional design, and I used a logistic regression
analysis. The predictors of retention as measured by > or equal to 12 months of retention and
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compliance as measured by positive drug screenings and attendance to all scheduled sessions
(individual/groups) were evaluated compared to reports of TA from the clients’ perspective
using logistic regression analysis. Demographic variables collected were also evaluated in the
same manner to control for their effect on the relationship between alliance, retention, and
treatment compliance.
I used the following research questions and hypotheses to guide this study:
Research Question 1:
Does positive therapeutic alliance as measured by the Session Rating Scale (SRS)
predict retention (as measured by length of stay in treatment) among patients receiving
methadone maintenance treatment?
Ha1: Report of positive therapeutic alliance as measured by a raw score of 36 or above
on the SRS will predict treatment retention measured as 12 or more months in MMT.
H01: Report of positive therapeutic alliance as measured by a raw score of 36 or
above on the SRS will not predict treatment retention measured as 12 or more months in
MMT.
Research Question 2:
Does positive therapeutic alliance as measured by the Session Rating Scale (SRS)
predict compliance (as measured by attendance to scheduled appointments) among patients
receiving methadone maintenance treatment?
Ha2: Report of positive therapeutic alliance as measured as a raw score of 36 or above
on the SRS will predict treatment compliance as measured by client’s attendance record
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showing three or less non-excused missed appointments over the preceding 12 months of
MMT treatment.
H02: Report of positive therapeutic alliance as measured as a raw score of 36 or
above on the SRS will not predict treatment compliance as measured by client’s attendance
record showing three or less nonexcused missed appointments over the preceding 12 months
of MMT treatment.
Research Question 3:
Does positive therapeutic alliance as measured by the Session Rating Scale (SRS)
predict compliance (as measured by results of drug testing analysis) among patients receiving
methadone maintenance treatment?
Ha3: Report of positive therapeutic alliance as measured as a raw score of 36 or above
on the SRS will predict treatment compliance as measured by client’s drug test results
showing fewer than three positive illicit drug results over the preceding 12 months of MMT
treatment.
H03: Report of positive therapeutic alliance as measured as a raw score of 36 or above
on the SRS will not predict treatment compliance as measured by client’s drug test results
showing fewer than three positive illicit drug results over the preceding 12 months of MMT
treatment.
Purpose Statement
The purpose of this quantitative research study was to develop an understanding of
the effects of TA on MMT. The intent of this study was to evaluate whether report of positive
TA can predict MMT retention and compliance. The purpose of this research was to offer
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another perspective to improve the effectiveness of retention in Methadone Maintenance
Treatment (MMT) by focusing on improving therapeutic alliance, with the goal of keeping
the cost factors of improvement low. This researcher proposed that clients that have a healthy
TA with their clinical staff will show evidence of stronger retention rates. This understanding
will allow treatment providers to design treatment that will better engage clients and address
issues of attrition by increasing retention and compliance rates for those within this level of
care.
The independent variable of this study was the client’s reported therapeutic alliance
with their assigned clinical staff as measured by the Session Rating Scale (SRS). The first
dependent variable was treatment retention as measured by categorizing continuous retention
as > or equal to one year. The second dependent variable was compliance and divided into
two components. The first component of compliance was measured over the last year of
MMT, by categorizing client’s attendance to scheduled sessions of individual and group as
attendance compliant or non-compliant with compliant being measured as < 3 non-excused
missed sessions. The other component of treatment compliance was measured by
categorizing clients as treatment compliant and non-compliant based on recorded drug test,
with positive compliance being measured as equal to or < 3 positive drug screenings.
The potential covariates: The following variables have been identified as potential
predictors by past research that were discussed in the previous section of “Studies
Addressing the Problem” and was collected through demographic information: Age, race,
gender, marital status, employment status, and current methadone dosing level or dosing
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level at discharge. These variables were added into the regression model to see if they also
play a role in retention and compliance.
Theoretical Framework
The theoretical framework of this study is based on therapeutic alliance and that
having a positive therapeutic alliance will increase retention and compliance with MMT.
Retention and compliance with MMT for opioid addiction reduces withdraw symptoms from
opioids, and contributes to prevention of infectious disease spread, prevents illicit drug use
and criminal activity associated with drug use, decreases overdose potential and interpersonal
difficulties (Ward et al., 1999; Reisinger et al., 2009; Krambeer et al., 2001).
Therapeutic alliance (Duncan, Sparks, & Miller, 2006) is commonly also referred to
as working alliance (Bordin,1979; Fitzpatrick & Irannejad, 2008; Marmarosh & Kivlighan,
2012), client and counselor rapport or relationship (Knox, Hess, Hill, Burkard, & CrookLyon, 2012), and helping alliance or relationship (Topor & Denhov, 2012; Ruglass, Miele,
Hien, Campbell, Hu, Caldeira, and ... Nunes, 2012). Therapeutic alliance describes the
relationship between the client and the counselor. Bernal, Bonilla, Alvarez and Greaux
(1993) simply described psychotherapy alliance as the relationship between the client and the
therapist. Bordin (1979) defined alliance as an agreement between client and therapist on
treatment goals, agreement on how to achieve the goals and the personal bond between the
therapist and client.
Positive client evaluations of the quality of social services, program accessibility and
informed dosing levels were found to be predictors of retention in a study of 351 opioid users
in MMT (Condelli & Dunteman, 1993). Kelly et al. (2010) found that clients who reported
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satisfaction with their counselors and programs were more likely to be retained in treatment
for at least 12 months. Reisinger et al. (2009) found that on top of program noncompliance
another factor that was highly related to discharge was conflict with their counselor. Trujols,
Garijo, Siñol, del Pozo, Portella and Pérez de los Cobos (2012) found that client participation
in treatment decisions and less negative effects of social functioning were more likely to be
satisfied with MMT. Zhang, Gerstein and Friedmann (2009) reported that independent of
treatment duration, counseling intensity, patient adherence to treatment protocols, pretreatment drug use patterns, and other characteristics of patients and treatment programs, a
favorable evaluation of treatment at discharge had a significant influence on positive
treatment outcomes. Joe et al. (2007) conducted a study of 497 MMT clients and categorized
them over 3 month intervals into improvers, decliners and continuing users. They found that
in the continuing user category clients reported lower TA and less time in treatment. The
majority of factors related to treatment program would seem to be somewhat influenced by
the counselor and thus a factor of the therapeutic alliance between the client and counselor.
Counselors work directly with the client and their treatment planning, usually are part of the
team deciding outcomes of policy infractions and implementation of social interventions for
the client. Clinical staff have influence on several internal factors that contribute to the
clients’ perception of the MMT program. Therapeutic alliance is a key factor in engagement
and retention in drug treatment (Meier, Barrowclough, & Donmall, 2005).
Deck and Carlson (2005) identified that numerous amounts of research have provided
evidence that duration of substance abuse treatment, especially with MMT, results in higher
rates of improved outcomes. This study has a goal of increasing retention rates within a cost-
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effective model. Therefore, this study aimed to evaluate the theory that TA is an important
contributing factor that would significantly improve retention rates (Palmer et al., 2009;
Kelly et al., 2010; Joe et al. , 2001; Meir et al., 2005). The aim was an evaluation of the
effect of TA for predicting increased retention and compliance in MMT. The discussion of
the influence of TA on treatment retention and compliance is discussed in more detail
through presentation of past research in Chapter 2.
Definition of Key Terms
Clinical staff: For the purpose of this study the clinical staff members include the
therapy staff member and the case manager.
Compliance: Compliance is defined as attendance to scheduled individual and group
sessions in MMT.
Group session: Group sessions are group substance use or mental health
psychoeducational or process group sessions that the client has been required to attend by the
clinical staff members and facilitated by clinical staff members. For the purpose of this study
it does not include AA/NA, Smart Recovery or other peer ran social support groups not
facilitated by a clinical staff member.
Individual session: An individual session is any session schedule with the client
between the client and clinical staff member for the purpose of counseling or treatment
progression discussion. This does not include appointments for administration of methadone
or prescriber evaluations.
Methadone: Methadone is a synthetic narcotic analgesic used for treatment of people
dependent on opioids (Center for Substance Abuse Treatment. Medication-Assisted
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Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville (MD): SAMHSA,
2005). Methadone is also used for other medical purposes such as treatment of pain
(Rosenblum, Marsch, Joseph & Portenoy, 2008, p.405; Toombs & Kral, 2005). but for the
purpose of this research the focus is purely on the treatment of opioid addiction. The purpose
of methadone is to keep the individual from experiencing withdrawal symptoms, control the
cravings for illicit use and when dose is sufficiently high enough it produces blocking of the
effects of illicit opioid drugs (Center for Substance Abuse Treatment. Medication-Assisted
Treatment for Opioid Addiction in Opioid Treatment Programs).
Methadone Maintenance Treatment (MMT): A program in which opioid addicted
individuals receive daily doses of methadone as a medical intervention, under the guidance of
a prescriber with monitoring. Methadone maintenance is a long-term therapeutic intervention
for dependence to heroin and other opiates (Centers for Disease Control and Prevention,
2002; National Institutes of Health, 1997).
Pharmacological interventions: For the purpose of this research the only
pharmacological intervention included is an agonist (methadone).
Psychosocial interventions: For the purpose of this research these were interpreted as
any non-pharmacological intervention carried out in a therapeutic structure by a clinical staff
member with an individual client or within the confounds of a group of clients.
Retention: Retention is defined as length of stay in MMT.
Substance Use Disorder: The newest version of the Diagnostic and Statistical Manual
(DSM): DSM-5 was released in May 2013. In this version of the DSM Substance Use
Disorder is a singular diagnosis which combines substance abuse and substance dependence.
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In order to be diagnosed with Substance Use Disorder the patient must meet at least 2 of the
11 criteria for the diagnosis. The criteria are very similar to those outlined in DSM-IV for
abuse and dependence combined. A patient meeting 2-3 if the criteria indicates mild
substance use disorder, meeting 4-5 criteria indicates moderate, and 6-7 indicates severe
(American Psychiatric Association (APA), 2013, 541).
Diagnostic Criteria in relation to Opioids
•

Continuing to use opioids despite negative personal consequences

•

Repeatedly unable to carry out major obligations at work, school, or home due to opioid use

•

Recurrent use of opioids in physically hazardous situations

•

Continued use despite persistent or recurring social or interpersonal problems caused or made
worse by opioid use

•

Tolerance as defined by either a need for markedly increased amounts to achieve intoxication
or desired effect or markedly diminished effect with continued use of the same amount

•

Withdrawal manifesting as either characteristic syndrome or the substance is used to avoid
withdrawal

•

Using greater amounts or using over a longer time period than intended

•

Persistent desire or unsuccessful efforts to cut down or control opioid use

•

Spending a lot of time obtaining, using, or recovering from using opioids

•

Stopping or reducing important social, occupational, or recreational activities due to opioid
use

•

Consistent use of opioids despite acknowledgment of persistent or recurrent physical or
psychological difficulties from using opioids
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•

Craving or a strong desire to use opioids (APA, 2013, p. 541)
Therapeutic Alliance: There are variations in the report of the definition of
therapeutic alliance, for the purpose of this study it will be defined as the ability of the
therapist and client to work together on common tasks and goals and the affective nature of
the relationship and identified by self-report of the participant, measured as a raw score of 36
or above on the Session Rating Scale.
Assumptions
1. The study is based on the prior evidence that suggests that methadone treatment is
the most effective treatment for opioid addiction and it is consistent across age, cultural and
gender dimensions.
2. The clients are able to form some type of therapeutic alliance with clinical
treatment providers through direct contact. Furthermore, that clinical staff makes adjustments
as necessary for cultural and other factors.
3. The SRS is a reliable and valid assessment instrument that will measure therapeutic
alliance among participants from the perspective of the client.
4. That retention in methadone treatment increases positive outcomes.
5. Participants were honest when scoring the SRS.
6. Participants accurately reported their drug use history, demographics and other
self-reported information.
7. Reports of the results of drug screenings are accurate.
8. The reports of number of sessions the client has attended are accurate.
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Scope and Delimitations
This study was based on research stating that report of therapeutic alliance increases
retention and compliance in social programs or interventions, and this study intended to
apply that same concept to evaluate if it also has the same effect in regards to MMT
specifically. But there may be numerous reasons for program retention and compliance. In
order to control for those potential variables that have already been researched, they have
been included in the demographic information and were included in the analysis.
Sociodemographic predictors for retention age at admission, keeping good
relationship with family, source of income, employment, race, education, marital status,
living in rural area and involvement in the criminal justice system (Maura, Nwakeze &
Demsky, 1998; Yang, Lin, Li, Long, Li, Luo, 2013; Zhang et al., 2013). This study will only
look at sociodemographic predictors available in the charts of the sample participants; age,
gender, employment status, race, marital status and peak dosing level.
The population included for the purpose of this study is opioid dependent
male/female clients, age 18+ years old, who have been receiving MMT for at least 1 year in a
non-profit agency in Arizona. Influences on external validity are presented in the limitations
section as are potential generalizability issues related to the population.
Limitations
1. A significant limitation of this study relates to the selection bias due to the small
sample size in comparison to the national population of MMT clients. In the United States
alone it is estimated that 151,882 clients are in outpatient methadone treatment for opioid
addiction (The National Substance Abuse Treatment System, 2003).
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2. The study only examined individuals that were enrolled in outpatient MMT
program treatment modality; therefore, those in a higher treatment level or in a different
environment (e.g. PCP office) might exhibit different retention rates.
3. There is also a possible geographic influence as the study’s target population is
limited to one state Arizona, so it is difficult to generalize to other areas of the nation. Results
from this study cannot be generalized to the population as a whole.
4. The study’s participants could possibly provide false answers on the self- reported
demographic information; thereby, the data would be inaccurate.
5. The study is limited to participants participating in MMT solely for the treatment
of opioid addiction and not pain management.
6. The study’s internal and external validity could be affected by the individual’s
previous treatment history, the existence a co-occurring disorder, age and gender of the
client, family history of SA, history of physical, psychological, or sexual abuse, or type of
substance being used.
7. Another significant limitation is within the measurement bias related to the selfreporting nature of the study from the clients’ perspective, clinical staff’s perspective and the
influence of the client and clinical staff desiring to present themselves in a favorable manner.
One other limitation is the intervention (exposure) bias related to the inability to ensure that
every survey question with each client was scored precisely in the same manner (This will be
discussed in more detail in Chapter 3 under the Session Rating Scale section).
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Significance of Study
This study contributes to the limited existing research on the effect of TA from the
clients’ perspective. The significance of TA within a target population of individuals in
outpatient MMT and the retention of these clients was fully examined, with the goal of
providing guidance to clinicians on developing treatment that will address improving alliance
to reduce attrition rates in MMT. The researcher anticipates that the findings of this study
will stimulate new treatment methodologies that would reduce attrition rates within MMT.
Social Change Implications
The goal of this research was to offer MMT a focus on TA which may be currently
understated in MMT in order to influence increased retention and compliance rates, thus
reducing the negative impacts and costs factors. Training and implementing a focus on TA to
increase successful MMT program treatment is an inexpensive, easily initiate and relatively
quicker method than reevaluating internal methodologies such as instructional materials. This
could allow the costs and risk factors to be reduced which is currently a concern in mental
health and substance abuse treatment.
Summary of Chapters
Research has linked that the length of MMT over 12 months is associated with lower
risks of relapse, criminal justice involvement, disease risks and improved quality of life
outcomes (Kayman et al., 2006). It takes time to stabilize areas such as returning to a
normalized brain functioning level, ability to control triggers and urges and stabilization in
environment (e.g. employment, housing, social and family relationships and etc.), and
success with MMT is more likely if there is stabilization in these areas. Therapeutic Alliance
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has been shown to have an impact on the progress a client makes in treatment (Joe et al.,
2007) and likelihood of clients being retained in MMT at 12 months (Kelly et al., 2010).
Chapter 1 provides a brief overview of the study’s purpose in examination of the
effect of TA. Chapter 2 reviews the literature delineating the effects on successful methadone
treatment. Chapter 3 details the research methodology used in the study. Chapter 4 reviews
the description of the sample, reviews the hypotheses, discusses the data collection process
and presents the results. Chapter 5 discusses the implications of the results, the limitations of
the study, summarizes and offers suggestions for future studies.
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Chapter 2: Literature Review
My purpose in this study was to evaluate whether therapeutic alliance is a predictor of
methadone treatment outcomes, defined as retention and compliance. The purpose of the
literature review is to review research supporting TA as a contributor for successful treatment
outcomes. Because there was limited research related to TA and methadone in combination, I
focused on two distinct subjects: TA and methadone maintenance treatment. The primary
factors related to successful treatment outcomes in MMT is retention and compliance in
treatment. I examined in the variable of therapeutic alliance as a contributor of successful
outcome defined by retention and compliance.
Organization of the Chapter
I will present a scholarly conversation on methadone treatment in general and TA
research and links why research into the effect of TA on methadone treatment retention is
warranted. This chapter begins with a description of the literature search and the results
related to how and why methadone treatment is one of the preferred forms of treatment of
opioid dependence, the definition of opioid dependence, and research prevalence of opioid
addiction. Discussion will include why opioid dependence is a significant problem,
alternative methadone treatment options, and goals of opioid dependence treatment.
Completing the discussion with the reason retention in methadone treatment is important,
history and research on TA in treatment, and how development of improving TA can be a
cost effective way to increase methadone maintenance treatment retention. The review
revealed the economic costs of opioid dependence and the costs to society. The literature
reviews on TA offered information related to success rates using therapeutic alliance for
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various disorders and treatment applications. The chapter ends with an overall summary of
the information presented. The literature review chapter expands on the introduction and
background information presented in Chapter 1.
Literature Search Strategy
The literature on the research gathered for this review was obtained from September
2008, to June 2014, from various journals at various libraries, and a variety of electronic
databases both through Walden University’s library as well as other university libraries and
online resources. The variety of electronic databases that were searched to gather relevant
resources included ProQuest, Academic Search Premier, ERIC, Funk and Wagnalls, Mental
Measurements Yearbook, PsycArticles, PsycBOOKS, PsycINFO, SocINDEX with Full Text,
PsycEXTRA, Psychology: A SAGE Full-Text Collection, Wiley Online Library and
Academic Search Complete/Premier, Google Scholar and Sciencedirect. Requirements and
regulations regarding opioid treatment programs were acquired through access of Title 42 of
the Code of Federal Regulations (CFR), Part 8. Online sites accessed for research included:
Texas Christian University, University of Phoenix Library, and Arizona State University
Library, US Department of Health and Human Services, National Institute of Drug Abuse
(NIDA), Centers for Disease Control, Psychotherapy.net, White Rose Research online and
SAMHSA. I acquired numerous hard copies of journals either through subscription or
through professionals who work in the field and allowed me to use their resources.
I used the following words or phrases in the search for articles: methadone, history of
methadone treatment, drop out from opioid treatment, retention, opioid treatment, substance
abuse, substitution therapy, opioids, opioid guidelines, indicators of successful treatment for
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methadone treatment, goal of methadone treatment, opioid abuse, opioid misuse, nonmedical
use of psychotherapeutic drugs, nonmedical use of opioids, history of methadone treatment,
counseling rapport, working alliance and therapeutic alliance. In addition, books, statistical
reports, and factsheets, and I reviewed websites sponsored by national research agencies such
as NIDA and SAMHSA to support the review.
As I conducted the literature review the utilization of methadone as a treatment of
opioid dependence was made clearer as well as defining successful methadone treatment. An
understanding of opioid dependence and its effects on society assisted with an understanding
of the need for successful treatment means and ways to recognize successful treatment. The
effect of TA within treatment modalities revealed how it contributes to the concept of
successful treatment regardless of the modality implemented.
The first section of this review addresses the history of methadone as a treatment for
opioid dependence, physical and psychological effects of opioid dependence, the economic
effects on society and a comparison of treatment for opioid dependence.
A Historical Perspective of Methadone Treatment for Opioid Dependence
During the 19th century opioids or medications with synthesized opium, were one of
the most prescribed medications (Leavitt, 2000). The consequence of this was an epidemic of
persons who became dependent on opioids. This epidemic affected people across socioeconomical lines and therefore with that factor and the mass of people who developed the
dependence, the problem came into public view. These opioid dependent individuals were
not just the undesirable, these were the middle and upper middle class that were mothers,
fathers, professionals therefore including white collar workers (Leavitt, 2000).
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The theoritical framework of this study is Methadone Matintence Therapy (MMT)
and that retention in MMT for opioid addictiton reduces withdrawal symptoms from opioids,
and contributes to prevention of infectious disease spread, prevents illicit drug use and
criminal activity associated with drug use, and decreases overdose potential and interpersonal
difficulties (Ward et al., 1999; Reisinger et al., 2009; Krambeer et al., 2001). Methadone
became a treatment for opioid dependence in 1964 as a response to post World War II opioid
dependence in New York City (Joseph, Stancliff, & Langrod, 2000). In the 1963 Dr. Vincent
Dole and Dr. Marie Nyswander conducted an experiment with chronic heroin dependent
persons utilizing pharmaceutical opiates to treat heroin dependence (National Alliance of
Methadone Advocates (NAMA), 2003; Leavitt, 2000). When Dr. Dole and Dr. Nyswander
did not get the results they desired and decided to use a synthetic opioid called methadone.
Methadone did not produce the sedated effects prior attempts at treating with pharmaceutical
opiates had, and yet the patients were no longer focused on drug seeking and returned to
activities they had participated in prior to their dependence (NAMA, 2003). This was when
methadone treatment was developed for opioid addiction.
Methadone treatment became a topic of discussion and went under great scrutiny
when it was suggested that methadone was as addicting (Winick, 2001). The difference was
that methadone was much less expensive and patients could continue to function in normal
activities day to day. Still the medical community and the public struggled with the idea of
exchanging one dependence for another. In 1998 Mayor Giuliani of New York City lobbied
against methadone maintenance treatment clinics (Winick, 2001; Leavitt, 2000) and in 1999
Senator John McCain introduced a bill to limit length of treatment with methadone (Leavitt,
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2000). The standard of clinics that exist today is harm reduction through maintenance
treatment. The current regulation of opioid treatment programs is laid out in Title 42 of the
Code of Federal Regulations (CFR), Part 8 and states all opioid treatment facilities must have
current valid certification through SAMHSA (section 303(g)(1) of the Controlled Substances
Act (21 U.S.C. 823(g)(1)). This regulation doesn’t stop lobbying against methadone
maintenance treatment or those in office from submitting bills to attempt to change the
regulation, but it does offer protection for Opioid Treatment Programs to provide methadone
maintenance within the regulations until something in the regulation changes.
What Is Opioid Dependence or Abuse?
Opioids are included in a class of drugs that encompass both natural and
synthetic drugs. There are four classes of opioids: Phenanthrenes (morphine, codeine,
hydromorphone, levorphanol, oxycodone, hydrocodone, oxymorphine, buprenorphine,
nalbuphrine, and butorphanol), Benzomorphines (pentazocine), Phenylpiperidines (fentanyl,
alfentanil, sufentanil, and meperidine) and Diphenylheptanes (propoxyphene and methadone)
(Trescot, Datta, Lee, & Hansen (2008). The source for all natural opioids is the poppy
papaver somniferum; there are synthetic opioids made in a lab and semi-synthetic opioids
which are a mixture of the natural opioids synthesized (e.g. heroin, oxycodone and
hydrocodone) (U.S. Department of Justice Drug Enforcement Administration, 2011).
Opioid dependence is a chronic, relapsing substance abuse disorder that is often lifethreatening and has high rates of mortality (Scherbaum & Specka, 2008). Life-threatening
describes the potential of over dose (OD), the potential of HIV/AIDS and potential dangers
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of the life style in general (Scherbaum & Specka). The American Psychiatric Association
(2013) describes the DSM-V criteria for substance use disorder as:
Substance Use Disorder: A singular diagnosis which combines Substance Abuse and
Substance Dependence. In order to be diagnosed with Substance Use Disorder the patient
must meet at least 2 of the 11 criteria for the diagnosis. The criteria are very similar to those
outlined in DSM-IV for abuse and dependence combined. A patient meeting 2-3 if the
criteria indicates mild substance use disorder, meeting 4-5 criteria indicates moderate, and 67 indicates severe (APA, 2013, 541).
Diagnostic Criteria in Relation to Opioids
•

Continuing to use opioids despite negative personal consequences.

•

Repeatedly unable to carry out major obligations at work, school, or home due

to opioid use
•

Recurrent use of opioids in physically hazardous situations.

•

Continued use despite persistent or recurring social or interpersonal problems

caused or made worse by opioid use.
•

Tolerance as defined by either a need for markedly increased amounts to

achieve intoxication or desired effect or markedly diminished effect with continued use of
the same amount.
•

Withdrawal manifesting as either characteristic syndrome or the substance is

used to avoid withdrawal.
•

Using greater amounts or using over a longer time period than intended.
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•

Persistent desire or unsuccessful efforts to cut down or control opioid use.

•

Spending a lot of time obtaining, using, or recovering from using opioids.

•

Stopping or reducing important social, occupational, or recreational activities

due to opioid use.
•

Consistent use of opioids despite acknowledgment of persistent or recurrent

physical or psychological difficulties from using opioids.
•

Craving or a strong desire to use opioids (APA, 2013, p.541).

Prevalence of Opioid Abuse in the United States
According to United Nations Office on Drugs and Crime (UNODC) (2011), 40% of
global opioid users are located in North America. The United States uses 80% of the world’s
supply of opioids (Manchikanti, 2007; Institute of Addiction Medicine (IAM), 2014). One of
the major contributors to this statistic is the abuse of prescription drugs which in the United
States rates second only to marijuana use (UNODC, 2011; SAMHSA, 2010). From 1992 to
2003 there was a 140% increase of opioid prescription painkillers (IAM, 2014), even though
narcotic analgesics are pain relievers that can become habit forming. Manchikanti, Helm II,
Fellows, Janata, Pampati, Grider and Boswell (2012) stated that narcotic analgesics
prescriptions exceeded 238 million in 2011. According to the 2010 National Survey on Drug
Use and Health (SAMHSA, 2011) there were 5.1 million abusers of pain relievers (opiates)
which does not include those abusing opioids for other than pain (illicit drug use). SAMHSA
further stated in that same report that one in six or 17.3% of those users of non-therapeutic
opioids had obtained opioids from a prescription written by a licensed physician. Perhaps this
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suggest that due to the use of opioids for pain treatment, the opioid dependence epidemic has
grown to more than just those that participates in illicit opioid drug use.
Effects of Opioid Abuse on Society
Ruetsch (2010) reported the costs of opioid abuse at around half a trillion dollars
factoring in social, medical and criminal related costs. Rinaldo, S. and Rinaldo, D. (2013)
stated that according to the 2011 report by the CDC illicit use of opioid pain relievers costs
U.S. health insurers approximately $72.5 billion dollars each year in healthcare costs, and
that the opioid overdose fatalities are comparable to those for motor vehicle incidents for
individuals under age 65. Disley, Mulcahy, Pardal, Rubin and Ruggeri (2013) conducted a
research study to look at evaluating the costs of opioid dependence in Europe, including:
health impacts (mortality, morbidity), effects on employment, impacts on children and
families, and crime and victimization. That study found that opioids were present in 80-90%
of the drug related deaths in Europe. The most common cause was overdose, followed by
trauma (e.g. accidents), suicide and disease-specific mortality (for example, HIV/AIDS and
liver disease). Sullivan, Metzger, Fudala and Fiellin (2005) stated that 10% of all new HIV
infections in 2003 were related to sharing of needles with injection drug users.
There are numerous potential work-related costs such as shutdowns or having to pay
to bring in temporary staff to cover shortages by those not coming in to work due to their
opioid abuse. Ruetsch (2010) stated that in the United States the National Survey on Drug
Use and Health (NSDUH) survey, individuals miss more than 2.2 days of work when abusing
opioids than those who do not abuse opioids (.83 days per month). Birnbaum, White,
Schiller, Waldman, Cleveland and Roland (2011) reported that $25.6 billion (46%) of costs
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are related to workplace losses in the United States. In 1996, Mark, Woody, Juday and
Kleber (2000) reported the overall loss of specifically heroin dependence was $21.9 billion,
of which the largest portion (52.6%) was related to the workplace indirect costs.
Impact on families of opiate abusers is difficult to measure, it is often an emotional
cost and thus studies reporting these costs as a monetary value were not located. But some of
the monetary costs for families would also include loss of monies due to loss of wages, court
costs, lawyer fees, providing monies to incarcerated individuals, treatment costs and other
costs.
Mark, Woody, Juday and Kleber (2000) stated that they found the cost of heroin
dependence related to criminal justice was $522 million. Birnbaum, White, Schiller,
Waldman, Cleveland and Roland (2011) identified criminal justice costs related to opioid
prescription abuse in 2007 was $5.1 billion dollars. Criminal justice costs include policing,
legal, incarceration and cost to crime victims.
The costs of opiate abuse effects more than just the United States. The overall social
costs for Canada was reported by Wall, Rehm, Fischer, Brands, Gliksman, Stewart…Blake
(2000) to be about 5.086 million Canadian dollars related to crime victimization (44.6%) and
law enforcement (42.4%), followed by productivity losses (7.0%) and the utilization of
health care (6.1%). The overall costs of opioid dependence are complicated and often not
fully able to be expressed in an easily applied monetary value.
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Medication Assisted Treatment Approaches for Opioid Abuse/Dependence and
Effectiveness
Clonidine, Levomethadyl acetate, Naltrexone, Buprenorphine, and methadone are
common medications used for treatment of opioid addiction. Clonidine is used to treat
withdrawal symptoms such as anxiety, agitation, muscle aches, sweating, runny nose, and
cramping but not as a long-term treatment to avoid relapse (Gold, Pottash, Sweeney, &
Kleber, 1980). Farrell, Wodak and Gowing (2012) stated that methadone and buprenorphine
are options for opioid treatment in 73 countries and offer the strongest evidence of
effectiveness than other treatments for severe heroin dependence.
Anesthesia-assisted rapid opiate detoxification (AAROD)
AAROD was developed during the 1980s and the goal was to reduce the discomfort
of withdrawal. Detox under anesthesia involves placing the individual under anesthesia and
injecting large doses of opiate-blocking drugs. There is controversy regarding this type of
detox due to several deaths associated with the procedures, particularly when it is done
outside a hospital. The Center for Disease Control and Prevention (CDC, 2013) conducted an
investigation into a clinic in New York City where it was reported that three individuals
experienced adverse effects that led to the death of one those. Of the 75 patients at that New
York City clinic who underwent AAROD over a nine-month period in 2012 it was reported
that two of the individuals died, and five others were hospitalized. Findings on AAROD
suggest it has a potential for high risk of severe adverse effects and it does not appear to
reduce subjective opioid withdrawal symptoms more than traditional opioid detoxification
modalities (CDC, 2013).
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Levomethadyl acetate
Levomethadyl acetate hydrochloride (LAAM) was approved in 1993 by the US Food
and Drug Administration for the treatment of opioid dependence (Jones, Strain, Bigelow,
Walsh, Stitzer, Eissenberg, & Johnson, 1998). LAAM works similar to methadone as it is a
µ-opioid agonist and produces opioid blockade, and due to the longer half-life dosing
frequency is only three times a week. Jones, Strain, Bigelow, Walsh, Stitzer, Eissenberg and
Johnson conducted a study with 180 individuals on three different levels of LAAM (low,
medium and high) doses for the purpose of induction. They concluded that higher does can
be safely achieved in 17 days but had risks of patient dropout. They further identified that
opioid agonist adverse effects are also higher than the low and medium doses in which safe,
stable induction can be achieved within seven days. An oral solution of levomethadyl acetate
HCl (ORLAAM) developed by Roxane Laboratories Inc. was approved in 1993 for treatment
of opioid dependence treatment for individuals that failed to show evidence of acceptable
response or intolerability to other forms of medicated opioid treatment. In 2003, Roxane
Laboratories, Inc. notified the Food and Drug Administration (FDA) that ORLAAM was
being discontinued. The FDA (2011) investigated and determined that ORLAAM oral
solution, 10 mg/mL, was not withdrawn for reasons of safety or effectiveness. Preda (2013)
reported that there have been several cases of cardiac arrhythmia and death related to LAAM
resulting in it being removed from the market in Europe and the FDA gave it a black box
warning in the US.
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Naltrexone
Naltrexone is an opioid antagonist; thus, it blocks the euphoric effects of opioids
(ADIS International Limited, 2012). In a review of 15 studies of 1076 clients there was
variation in the reporting of effectiveness of naltrexone in treating opioid dependence; the
variable that influenced the effectiveness appeared to be retention in treatment and in with
high retention there did appear to be significant evidence of reduced positive opioid positive
drug screenings (Johansson, Berglund, and Lindgren, 2006). Minozzi, Amato, Vecchi,
Davoli, Kirchmayer and Verster (2011) conducted a review of 13 studies with 1158
participants that compared those treated with naltrexone versus placebo or no
pharmacological treatments. This study showed no statistically significant differences,
therefore the authors determined there was no evidence to support naltrexone as a
maintenance therapy.
Buprenorphine
The FDA approved buprenorphine products for use in opioid addiction treatment

at the end of

2002. Buprenorphine is a m µ-opioid partial agonist that suppresses withdrawal and cravings,
but it also works as a partial antagonist which means it has a "ceiling effect" (Ling and
Smith, 2002). Ceiling effect means that individuals prescribed buprenorphine achieve a dose
level where higher doses cause no additional effects, leading to less potential of overdose
(Preda, 2013). Buprenorphine is an opioid, and therefore individuals may still experience typical opioid
agonist effects such as euphoria and respiratory depression but at its “ceiling effect” those effects are no longer
experienced. Farrell,

Wodak and Gowing (2012) report that retention with buprenorphine in
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treatment is lower than with Methadone treatment; for every nine individuals receiving
methadone treatment, one more than treated with Buprenorphine will be retained.
Methadone maintenance treatment (MMT)
Development of MMT occurred in the U.S. around 1964 when it was used as a
medical response to the heroin epidemic in New York City related to vets returning from
World War II (NAMA, 2003). Dr. Vincent Dole and Dr. Marie Nyswander conducted an
experiment with chronic heroin dependent persons utilizing pharmaceutical opiates to treat
heroin dependence (NAMA, 2003). They did not get the results they desired and decided to
use a synthetic opioid called methadone. What they found is instead of the sedated effects
prior attempts at treating with pharmaceutical opiates had, the patients were no longer
focused on drug seeking and desired to return to activities they participated in prior to their
dependence (NAMA, 2003); methadone treatment was developed. Farrell, Wodak and
Gowing (2012) stated that methadone is an option for opioid dependence treatment in 73
countries and offers the strongest evidence of effectiveness compared to other treatments for
severe heroin dependence.
Methadone hydrochloride is a synthetic opioid agonist at the m-opioid receptor that
persists for up to 48 hours after oral administration. Methadone maintenance treatment
(MMT) is one of the most widely known pharmacotherapy treatments for illicit opioid
dependence (Krambeer, McKnelly, Gabrielli, & Penick, 2001). At therapeutic dosages,
methadone appears to suppress opioid cravings and the preferred therapeutic treatment is at
doses of 50 mg. or higher (Farré, Mas, Torrens, Moreno, & Camı́, 2002). The goal of MMT
is to help opioid drug users return to productive lives and with methadone actual monetary
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costs are less than buprenorphine (Farrell, Wodak, & Gowing, 2012). ADIS International
Limited (2012) state that MMT has been associated with a reduction in criminal behavior and
HIV risk behaviors. One serious potential risk with methadone is misuse and overdose and
the risks are highest in the first month of treatment (ADIS, 2012).
Opioid Dependence Treatment Goals
The Federation of State Medical Boards (2013, p.3) stated that “the primary goals of
addiction treatment are to reduce or stop opioid use, to improve the patient’s overall health
and social functioning, and to help the patient avoid some of the more serious consequences
of opioid addiction.” The approaches in methadone treatment to achieve these goals range
from harm reduction, to long-term maintenance, to abstinence from all illicit drugs.
Goals of MMT are to address the issues stated previously: reduce high rates and costs
of medical issues (e.g. HIV disease spread and overdoses), reduce criminal related costs,
reduce dependence on government funded programs caused by unemployment rates, and
improve overall social functioning. There is some heterogeneity in the research related to
which treatment is the most cost-effective to treat opioid dependence but the majority state
that methadone is cost-effective (Barnett & Hui 2000; National Institutes of Health, 1997).
Importance of and Factors of Retention in Methadone Treatment
Research has shown that the first year of MMT is critical mile marker in successful
outcomes, and discharge prior to this is often related to clinic policy (Reisinger et al., 2009).
Research studies have found that high rates of relapse to opioid use when methadone
treatment is discontinued such as due to programs that focus on detoxification and dose
reduction towards abstinence (Magura and Rosenblum, 2001; Gossop, Marsden, Stewart, &
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Treacy, 2001). Return to illicit opioid use also means a return to opioid use behavior,
criminal activity, high risk disease spread behavior (e.g. sharing needles), decreased prosocial and family activities, reduced stable employment leading to more dependence on
government funded programs, and higher mortality rates. A study of 307 opioid dependent
individuals found that participants were 3 times more likely to die when not participating in
MMT (Caplehorn, Stella, Dalton, Cluff, & Petrenas, 1994).
Rates of retention are significantly lower in programs that discharge clients related to
rule violations and financial inability to pay (Deck & Carlson, 2005; Strike, Gnama,
Urbanoskia, Fischer, Marsh, & Millson, 2005). Mitchell, Morioka, Schacht Reisinger,
Peterson, Kelly, Agar, and et al. (2011) reported that clients’ perspective of recovery was
based more on positive progress forward toward their goals that may include some steps
backwards (e.g. relapses) during the process.
If we look at comparing length of treatment, Farre, Mas, Torrens, Moreno, and Cami
(2002) reported retention rates from 20% at 17 weeks to 85% at 40 weeks. Strike, Gnama,
Urbanoskia, Fischer, Marsh and Millson (2005) found in a study conducted in Italy, that
client’s retention rates were as high as 40% at one year of MMT and 50% of patients
remained in treatment for 730 days or more. They further found that methadone dosage, age
and clinic policy were the most important factors determining retention, while number of
treatment episodes decreased likelihood of retention. Fortuin Corsi, Kwiatkowski and Booth
(2002) stated that at interviews conducted with clients participating in MMT at 5-9 months,
the best predictor of positive outcomes appeared to be still being in treatment and length of
treatment.
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Much of the research on retention in MMT has provided evidence of the effect of
dosing levels on methadone treatment retention (Amato, Davoli, Perucci, et al., 2005;
Gossop, Marsden, Stewart, et al., 2001; D'Ippoliti, Davoli, Perucci, et al., 1998; Farré, Mas,
Torrens, Moreno, & Camı́, 2002). There has been no agreement on the level of effective
methadone dosing.
The Theory: Therapeutic Alliance
The field of substance abuse has been slower than other fields in embracing research
on the effect of therapeutic alliance on treatment outcomes (Ritter, Bowden, Murray, Ross,
Greeley, &Pead, 2002). Perhaps in part it is due to the history of treatment such as
therapeutic communities in which practices existed that focused on tearing a client down and
then rebuilding them. There was no research found that explained why substance abuse has
been delayed in evaluating therapeutic effect on treatment outcomes. Other fields such as
mental health, medical practitioners and nurses are researching the relationship of TA and
treatment outcomes with various diseases and disorders, symptoms reduction, environments
and difficult client cases.
Examination of the therapeutic relationship and its influence has been examined as far
back as Freud in 1912. Freud was “aware of deep and intense feelings emerging in the
therapeutic relationship” and that these feeling may influence the therapist-client relationship
(Pereira, 2010, p. 2). The actual term “therapeutic alliance” was introduced in 1956 by
Elizabeth Zetzel as she described the condition of the relationship between the clinician and
the client that was a needed component of transference in order for effective analysis to occur
(Catty, 2004). Carl Rogers (1957) discussed his view of how “constructive personality
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change” could occur, identifying that the therapist needs to hold an unconditional positive
regard for the client and provid empathic understanding while communicating this to the
client.
Orlinsky, Grawe and Parks (1994) identified that the relationship between the
therapist and the client mediated the quality of client participation in treatment and that
participation was the most important determinant of outcome. Duncan et al. (2006) stated
that research has shown that most of the variance of outcomes in therapy is accounted for by
extratherapeutic factors, which are characteristics that facilitate growth from the client and
their environment and the TA. Duncan et al. further pointed out that research by Lambert
(1992) suggested that 40% of the variance in therapy outcomes was attributable to the clientextratherapeutic factors and he identified that 30% was attributable to the therapeutic
relationship. Thirty percent may contribute a large impact to the outcomes of therapy.
Martin, Garske and Davis (2000) conducted a meta-analytic review of 58 published
and 21 unpublished studies and found that TA was related to outcomes moderately but
consistently regardless of other influences. Knuuttila, Kuusisto, Saarnio and Nummi (2012)
found that client alliance ratings in the early stages of the therapeutic relationship were
significant predictors of treatment satisfaction at follow-up.
Factors influencing perception of therapeutic alliance
Alliance is the relationship, defined by Merriam Webster Dictionary as:
1: a bond or connection between families, states, parties, or individuals e.g. a closer
alliance between government and industry
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2: an association to further the common interests of the members; specifically: a
confederation of nations by treaty
3: union by relationship in qualities
Results by Marmarosh and Kivlighan (2012) suggested that as the therapist and client
exhibit more evidence of a positive perception of alliance at the early stages of treatment that
there are less reports of negative symptoms. Ritter, Bowden, Murray, Ross, Greeley, and
Pead (2002) stated that certain characteristics of the client may influence the outlook on the
TA. They noted that with the clients they studied, those with anxiety or lower cognitive
functioning viewed the counselor as exhibiting less therapeutic tendencies and that affected
the response to treatment as well as the outcomes of treatment. Bordin (1979) acknowledged
the influence of personality of the clinical staff member and of the client influences each in
meeting the needs of the other. Meier, Donmall, Barrowclough, McElduff, and Heller (2005)
noted that clients who reported higher motivation levels, positive coping strategies, strong
social support and a secure attachment style reported a higher likelihood of developing good
alliances. Deering, Horn and Frampton (2012) conducted a survey of 93 clients receiving
opioid substitution treatment (OST), and found that characteristics such as being employed
improved reports of treatment satisfaction, while use of benzodiazepine and longer treatment
duration (with females) resulted in lower treatment satisfaction. They also found that overall
findings indicated a general satisfaction with OST and that in their study many of the
participants spoke highly of their clinical staff. Due to this Deering, Horn and Frampton
offered key strategies to improve the quality of OST treatment that included many things
controllable by staff that would be defined as part of the TA.
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The influence of therapeutic alliance on treatment
Joe, Simpson and Broome (1999) found that a strong correlation existed between the
subjective components that consisted of ratings of therapeutic involvement (therapeutic
alliance) between counselor and client and drug treatment compliance outcomes, including
illicit drug use and session attendance. Horvath and Symonds (1991) conducted a metaanalysis of 24 studies, and found there was a reliable, consistent relationship between the
working alliance (WA) and therapy outcomes. This relationship existed regardless of the
therapeutic approach, length of treatment and number of participants in the study. They also
noted the WA was the most predictive factor related to treatment outcome. Arnow,
Steidtmann, Blasey, Manber, Constantino, Klein, and... Kocsis (2013) found that regardless
of whether cognitive behavioral therapy approach or brief supportive psychotherapy
approach was utilized TA was a predictor of outcome. Cournoyer, Brochu, Landry and
Bergeron (2007) found that in a study of 248 clients in a drug rehabilitation program there
was an increased rate of drop out from treatment when the clients’ perception of the
counselor was that they lacked understanding, were less involved and when counselors did
not believe in the clients’ perseverance to treatment. Cooley and Lajoy (1980) found in a
study in a mental health clinic that client perceptions of their therapist as understanding and
accepting were correlated most highly with self-reported improvement. Barber, Connolly,
Crits-Christoph, Gladis and Siqueland’s (2009) findings agreed with numerous other studies
that early TA predicted the outcome of psychotherapy. Early working alliance between client
and therapist consistently predicts retention in substance abuse treatment (Meier et al., 2005;
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Knuuttila, Kuusisto, Saarnio, & Nummi, 2012; Crits-Christoph, Johnson, Connolly Gibbons,
& Gallop, 2013).
Effect of therapeutic alliance on treatment retention
The length of stay in treatment is one of the most consistent predictors of reduced
drug use, fewer arrests, decreased unemployment, and a reduction in health risk behaviors
among adults in substance abuse treatment (Simpson, Joe, Broome, Hiller, Knight & RowanSzal, 1997; Simpson, Brown & Joe, 1997; Joe et al., 2009). Safran and Muran (2000) suggest
that research has provided the evidence that early development of therapeutic alliance affects
the treatment outcome and therefore it is the key to resolve issues related to alliance in order
to improve outcome.
Brocato and Wagner (2008) found in a study of 141 male offenders that were
mandated to long term residential drug treatment that motivation to change was related to
retention in treatment, and motivation to change was related to positive reports of TA and
response to treatment, although they did not find a direct length to reports of positive TA
reports and length of treatment. They did identify that mandated clients may be more focused
on leaving treatment if there are no legal consequences than remaining in treatment. This
factor could influence the length the stay.
De Weert-Van Oene, G., Schippers, G., De Jong, C. and Schrijvers, G. (2001)
reported in their study of 93 clients enrolled in an inpatient treatment that the clients’
perception of the TA was one of the important factors in treatment retention predictors.
Knuuttila, Kuusisto, Saarnio and Nummi (2012) stated that next to amount of time abstinent,
the early report of positive TA by the clinician predicted treatment retention. Kasarabada,
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Hser, Boles and Huang (2002) stated that clients that reported more favorable opinions of
their counselor showed evidence of longer treatment retention in outpatient treatment. Meier,
Donmall, McElduff, Barrowclough and Heller (2006) conducted a study with 187 clients in
residential drug treatment in the UK and found that stronger reports of TA resulted in longer
retention in treatment.
Ruglass, Miele, Hien, Campbell, Hu, Caldeira and ... Nunes (2012) conducted a study
with 223 females with a diagnosis of with posttraumatic stress disorder (PTSD) and
substance use disorders examining the effect of TA on treatment outcomes. They had two
groups they examined; the first was a cognitive behavioral treatment called Seeking Safety
and the other was a Women’s Health education group. TA reports were significantly more
positive in the Seeking Safety group, although it did appear in both groups more positive
reports of alliance resulted in a decrease of PTSD symptomology and better attendance.
Teaching clinical staff therapeutic alliance skills
An important assumption of this study in regards to its social contribution is that
therapeutic alliance can be taught. For the purpose of this research the underlying benefit of
evaluating the effect of TA is in order to improve the quality of the alliance and thus impact
potential quality of treatment with retention in services. If the effect of TA is substantiated,
then later research may look at the qualities and characteristics of the therapeutic relationship
that can be changed and taught to clinical team members.
Sharpley, Tabary-Collins, Bates, Lee and Fairne (2000) found while being good
listeners is important, a balance of listening and responding effectively may be looked on
much more favorably by clients. Learning when to respond and how to respond is a skill that
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can be taught and learned by clinical staff. Contrary to what some schools have taught, this
study found that counselors with greater amounts of verbosity received higher ratings of
rapport than counselors who exhibited less verbosity. Sharpley, Jeffrey and McMah (2006)
further found that facial expressions that clinical staff use with the client conveys nonverbal
communication and can have a significant effect on reports of the clients’ perception of
rapport. It would be assumed that clinical staff could become aware of their facial
expressions and be able to manage them, perhaps through practice in a mirror or other means.
Knox, Hess, Hill, Burkard and Crook-Lyon (2012) found that how a clinician
responds to a client can assist the client in experiencing corrective relational experiences
(CREs). It is within the therapeutic relationship that the client can experience an awakening
in the area of experiencing the value of a healthy relationship, and then can begin to apply
that to their other relationships. Levensen (2003) discusses how the difficult clients with
maladaptive relationship skills can see how the therapist responds to them differently than
others have and can begin to apply that knowledge in knowing they too can interact
differently in their current relationships. This takes the skill of the therapist to respond
appropriately, be helpful, supportive, and patient, and to avoid negative response to the client
that could damage the therapeutic relationship they are trying to build. Once again it would
appear that traits such as being helpful, supportive, patient and knowing how to avoid
responding negatively could be taught to clinical staff. Safran and Muran (2000) wrote
“Negotiating the Therapeutic Alliance” for guidance for the clinician is not only in
recognizing negative processes and therapeutic impasses, but in learning how to manage
them within the confines of the therapeutic relationship. Saffran and Muran emphasize the
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importance of training of clinicians to deal with the negative processes and therapeutic
impasses they encounter. Falkenström, Granström and Holmqvist (2013) repeat the
sentiments of Safran and Muran, by producing results that show the importance of therapists
paying attention to ruptures and work on repairing the therapy alliance.
Summary
This chapter presented the literature associated with methadone maintenance
treatment and TA. The review revealed that the prevalence of opioid abuse and the issues
related to it (crime, health care and other social factor costs) are significant in the United
States. It also provided evidence that methadone maintenance treatment for opioid is a
successful and necessary treatment approach. This chapter further provided evidence that
retention in methadone maintenance treatment is imperative to successful outcomes and
therapeutic alliance may be an important factor in creating retention in methadone
maintenance treatment. The mutuality of the relationship in therapy reveals that there are at
least two individual perspectives on the therapeutic relationship. The chapter closed with
acknowledging that at least some of the components of characteristics (learning when and
how to respond, nonverbal and etc.), that affect therapeutic alliance can be taught to
clinicians, and that it is the clinical staff’s responsibility to repair damage to therapeutic
alliance.
In Chapter 3, the research design of the study is discussed. The discussion includes a
description of the population and instruments that were used to explore the relationship
between therapeutic alliance from both clients’ and the clinical staff’s perspective and the
effect on methadone maintenance treatment retention.
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Chapter 3: Research Method
I sought to evaluate the effect of therapeutic alliance specifically on MMT retention
and compliance. By focusing on MMT, my goal was to offer another perspective to improve
the effectiveness of retention and compliance in MMT by focusing on improving TA with
existing staff, as opposed to spending additional money on hiring more staff, buying group
materials, or other items. This researcher proposed that clients who have a healthy TA with
their clinical staff will show evidence of stronger retention rates and compliance.
The purpose of this chapter to provide a clear overview of the study’s design, as well
as the reasoning for this design selection. This researcher explained the proposed sample
characteristics and size, discussed the data collection process and analysis, and explored the
ethical considerations surrounding this study.
The independent variable was therapeutic alliance and this researcher collected the
data for therapeutic alliance from clients by accessing a database of the four clinics ran by the
agency used for this study. The agency that provided the data for this study collects the
information from every SRS at each session. On the SRS, positive TA is measured as scores
of 36 or greater. There is no cut off score that would imply a negative alliance, but all scores
under 36 are reviewed with the client as the score implies there may be some issue within
one or all of the four scales of the SRS. In the Measures section of this chapter I discuss the
reasoning for using this instrument, process of collecting the data with this instrument,
validity and reliability, and other instrument details.
I intended to examine whether participant-reported level of TA (the independent
variable) was associated with improved outcomes as defined by the retention (length of stay)
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and compliance (attendance to scheduled group/individual sessions and drug screenings). I
hypothesized that high levels of reported TA by participants would result in retention (of at
least 1 year) and higher levels of compliance (fewer positive drug screenings and higher rates
of attendance to scheduled sessions). The dependent variables (DVs) were treatment
retention, as measured by categorizing retention as 1 or more years and compliance divided
into two components. The first component of compliance was measured by categorizing each
participant’s attendance to scheduled sessions of individual and group as attendance
compliant or noncompliant, with compliance being measured as 3 or less nonexcused missed
sessions per year. The other component of treatment compliance was measured by
categorizing participants as treatment compliant and noncompliant based on recorded drug
test, with positive compliance being measured as less than 3 positive drug screenings within
a year. The nonparametric measure was logistic regression. This researcher performed he
statistical analysis using SPSS (V.21).

Research Design and Approach
In this quantitative cross-sectional study, I used a logistic regression analysis in
testing the proposed hypotheses. Archival data was used for the analyses in the present study.
The data was accessed using a database through an agency in the state of Arizona. The
agency used for this study collects various information including client demographic
information, drug screenings, session attendance and the results of a TA measure (SRS) from
each patient session. This research design is consistent with Hopkins (2000) who claimed
that, in quantitative research, the aim is to explore the relationship between the independent
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and dependent variables. Measures of the predictor variable of participant perceptions of
therapeutic alliance, and the criterion variables of client compliance and retention, were
gathered from the clinic records of randomly selected clients who had participated in
methadone maintenance treatment at the agency used for this study and who were living in
Arizona at the time of their MMT.
The present study was conducted using a quantitative method of inquiry wherein
numerical data was collected to explain or predict a phenomenon of interest, it was then
converted into categorical responses. Logistic regression is a regression model where the
dependent variable (DV) is categorical. All data analyzed for this study was sorted and
organized as categorical data. For the purpose of this study, the goal was to gain a clearer
understanding of the role of TA on retention and compliance in MMT. Dichotomous indices
were computed as follows: Therapeutic alliance was coded as positive (Y) if scores on the
SRS were greater or equal to 36 and negative TA was coded (N) for total SRS scores of less
than 36. Retention was coded as successful if the client was retained for one year or more
(Y); otherwise it was coded as unsuccessfully retained (N). Successful compliance (Y) for
drug screening results was coded for those clients whose drug screening reports were
negative for any drug other than methadone less than 3 times in a twelve-month period. A
case was coded as noncompliant (N) for those clients who show positive drug screenings 3 or
more times in a twelve-month period for any drug other than methadone. A case was coded
as successfully compliant (Y) for attendance for those clients who had 3 or less unexcused
missed attendance sessions in a twelve-month period. A case was coded as noncompliant (N)
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for those clients who had more than 3 unexcused missed attendance sessions in a twelvemonth period.
From the time of approval by the IRB to the retrieval of the data held in the database
by the agency it was four months. A specific report of all the data needed for this study was
programmed by the developers to protect access to other information in client charts not
needed for the purpose of this study. Once the data was received it took 4 more months to
sort through all the data to organize it and an additional two months to complete the analysis
of the raw data.
The first step was to review the data looking for missing items, outliers, and review
whether the sample meets the assumptions of normalcy required by the proposed analysis.
All relevant variables were computed and categorized based on the criteria described
previously. A descriptive analysis was then computed calculating frequencies, percentages,
means, medians, modes and SD for all relevant variables (e.g. demographic variables,
predictor variables, and criterion variables). The initial analysis was completed using a
jackknife approach with logistic regression. In testing TA (as measured by the SRS), the first
step in the analysis was to remove case one from the complete data set. A logistic regression
analysis using SRS scores for the report of TA as the independent variable was completed
using the other 263 cases. Then the removed case was tested against the model built by the
logistic regression analysis. Then, the second case was removed, and the same process as
described above was completed. This strategy of remove one case, build the model, test the
one case was completed a total of 264 times (for all 264 cases in the dataset). The series of
analyses provided information on the relative strength of the SRS in predicting retention.
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Furthermore, the remove one-build the model-test the case classifications provided valuable
information about the effectiveness of a jackknifed logistic regression model for those in
MMT in Arizona.
In testing compliance (measured by drug screening results), a logistic regression
analysis using SRS scores for the report of TA as the dependent variable was completed
using the other 263 cases. Then the removed case was tested against the model built by the
logistic regression analysis. In addition, the test classified the case as treatment compliant or
non-compliant (based on drug screening results). Then, the second case was removed, and
the same process as described above was completed. This strategy of remove one case, build
the model, test the one case was completed a total of 264 times (for all 264 cases in the
dataset). To evaluate session attendance for compliance, the same steps were again repeated
for the 264 cases as done for drug screening results, only this time the test classified the case
as treatment compliant or non-compliant (based on attendance for sessions).
To be included in the study the client participant had to be over the age of 18 and be a
current or discharged client consistently receiving administration of methadone through the
approved non-profit methadone maintenance treatment clinic (at the agency used for this
study) in the state of Arizona. Demographic information related to age, race, gender, and
marital status were collected on each participant through review of the database information
from client charts. Details of how this study addressed confidentiality and anonymity are
provided in the procedures section of this chapter.
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Population
The target population for this study was adults over the age of 18 who were receiving
or had received MMT for opioid dependence, in one of the four methadone maintenance
treatment outpatient programs run by the agency used for this study in the state of Arizona.
In addition to aforementioned criteria, there needed to be availability to sufficient data
required for this study; demographics, SRS scores, drug testing results and attendance
records. For the purpose of this study, the clinic was a state funded treatment program. Due
to HIPPA regulations it is very difficult to track the numbers of clients involved in private
pay methadone maintenance treatment that could occur through primary care physicians
(who have the appropriate credentials) or other private inpatient and outpatient facilities as
there is no central data base that offers that information. The agency that runs the MMT
programs used for this study serves private pay clients, insurance and AHCCCS (which is
Arizona’s program for Medicaid) and all types of payment clients were included in the study.
The original population consisted of 926 participants who had or currently were
receiving methadone maintenance treatment services from one of four methadone clinics in
Arizona, operated by the agency used for this study. After sorting through all the data for the
926 participants, 264 participant’s data included all the components needed for this study.
Demographics that were gathered from archival data on the participants for the
purpose of future studies. The demographics collected included clinic, age, gender, race,
employment status, and marital status. The effect of these demographic variables has been
researched previously in regards to MMT retention and compliance (Clausen et al., 2009;
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Yang, Lin, Li, Long, Li, Luo, 2013; Zhang et al., 2013; Huissoud et al., 2012) but they were
not analyzed in this study.
Sampling
There were three different reports of client’s information that was utilized for this
study from clients at four different methadone maintenance clinics. The three reports were
the participant list, SSRS/ORS scores and drug screening results. After sorting through the
data of the original 926 participants, 264 participants were selected into the sample because
those cases included all the information needed for this study. The remaining participants
were eliminated from the study for missing critical data (no ORS/SRS scores, insufficient or
no reports of drug screenings, or because of different classification used by some of the
clinics reports made it impossible to match critical pieces of data with the appropriate
participant).
To be included in the sample, participants had to be currently enrolled or discharged
from participating in MMT for opioid addiction at a licensed and publicly funded facility at
the agency used for this study, in the state of Arizona and participated in the MMT program
for a period of at least one year. To be eligible for this level of care, individuals must have
had an opioid use affect their lives in some manner. For the purpose of this study, the clients
that were currently enrolled but had not been receiving services for at least 2 years were
excluded from the study.
The proposed sample size for this study was established by using Cohen’s table
(Cohen, 1992; p. 158) to estimate the number of participants needed. For one predictor of
therapeutic alliance a sample size of at least 76 participants per group of clients would be
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required to ensure adequate power to detect medium treatment effects with an alpha set at .05
and a power of 80. This study had 264 participants, thus meeting the criteria for power.
Overview of the agency used for this study their MMT Program
The agency used for this study is a non-profit community-based provider of
behavioral health and substance use services located throughout the greater Phoenix area and
rural Maricopa, Gila, Pinal, Mohave, Coconino, and Yavapai Counties in Arizona. They
currently have more than 115 sites and over nine hundred employees. The agency used for
this study was established in 1969 as a federally funded program and became incorporated in
1974 as a 501(c) 3 non-profit.
The agency used in this study believes that recovery is possible and that
pharmacological management is a vital tool in the recovery effort. Methadone and Suboxone
services, unlike other substance abuse treatment, they are not based on a program of
abstinence. Methadone Maintenance treatment is a long-term process that is individually
paced and may require lifelong participation in the program. The agency’s methadone
maintenance program used in this study, offers counseling (individual, family, and group),
case management, psychiatric evaluations/medication monitoring along with methadone and
suboxone (Opioid Assisted Treatment). The aforementioned service and any additional
services are put into the client’s treatment plan.
The program performs random urine screenings for drugs. Missed screenings are
considered to be a positive indication of substance use, and refusal for drug screenings along
with positive drug screenings are monitored and reviewed with the client in staffing’s. A
possible result of too many positive drug screenings or non-compliance to other conditions of

55
the treatment plan could result in discharge from the program. The agency used for this study
does not immediately discharge for non-compliance; through staffing with the client, updated
goals, reinforcement of current goals, dosing level decisions are reviewed and addressed to
offer the client the best opportunity at success. Non-compliance is taken seriously and on
some occasions, continued non-compliance can result in administrative detox and discharge
from the MMT program.
Procedures
This study was presented to the Institutional Review Board (IRB) of Walden
University for review because the proposed methodology involves information of individuals
engaging in MMT. This researcher also contacted the Chief of Clinical Services for the
agency used for this study and arranged a meeting to discuss the research process. During the
meeting, this researcher provided an overview of the research process. The procedures were
explained, and that it did not appear that were any potential issues that would impact their
clients directly. Also discussed were any potential issues that could impact their clients for
example if somehow the data were compromised during transmission, or hard copy data got
into the hands of anyone outside of the study. All security precautions this researcher would
be taking were discussed. After all the questions and concerns were discussed, the Chief of
Clinical Services signed a Data Use Agreement (See Appendix A). In order to keep each
individual’s data confidential, numbers were utilized in place of names on all research
material. Confidentiality is a key factor in research. Since the study was conducted using
archival research method, drawn from clients’ record review, a prior consent was not
required. After IRB approval the archival data was obtained from three different databases
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through the agency used for this study from the four methadone clinics they operated. A
specific report of all the data needed for this study was programmed by the developers to
protect access to other information in client charts not needed for the purpose of this study.
Data was sorted and imported into an excel spreadsheet. The data was then imported into
SPSS (V.21) for analysis.

A rational for the utilization of existing agency data was offered by Dobrof, Dolinko,
Lichtiger, Uribarri and Epstein, (2002), whereas they suggested: it is less intrusive on clients
and staff, issues are avoided that come up with low response rates and time consumptions
noted with questionnaires and data is more agency relevant. Archival data also exhibits
strong external validity. All the data from cases in a database of information for each of the
treatment sites kept by the agency used for this study were reviewed. The data from Session
Rating Scales (See Appendix B) completed by the clients over the last 12 months of their
MMT program was collected from the database maintained by the agency used for this study.
I also received each subject’s demographic information, drug screening results and treatment
sessions attendance records that are held in an electronic database. After all the data was
gathered, each client was assigned a number that was recorded on the data sheet from the
review of participants’ data. Their names were not recorded to protect their anonymity. The
data collected was entered into and analyzed by this researcher using SPSS 21. Any client
with omitted information from the SRS, drug screening results, session attendance or missing
admission/discharge data was omitted from the study. The evaluation for omitted information
was conducted on each randomly selected participant from the database of the agency used
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for this study until there was no missing data for any of the cases in the sample. All
information for continuing subject information was stored in a locked file cabinet in my
home and the remainder data were destroyed. At the time of data collection and analysis the
researcher did not work for the agency involved in this study, but the researcher had
previously worked for the agency. The researcher did not work in methadone treatment and
thus did not have interaction with participants involved in this study to the best of the
researcher’s knowledge.
Measure: Session Rating Scale
The original Session Rating Scale (SRS) was created by Lynn Johnson in the early
1990s to help track his own progress with clients. Elements of each measure were combined
and converted into a 10-item, Likert-scaled instrument. The original SRS consisted of 10
items, but there were complaints about the time needed to complete the SRS. The SRS V.3
was developed to address this issue and consisted of 4 items that combined identified
measures of therapeutic alliance that clinical staff could review for each session. The Session
Rating Scale Version 3.0 (SRS V.3) was developed by Lynn D. Johnson, Scott D. Miller and
Barry L. Duncan in 2000 as an ultra-brief alliance measure of “working” alliance designed to
be utilized for every session. Permission to use the SRS was granted for this research by
Scott Miller, one of the developers of the SRS (See Appendix C and Appendix D). The SRS
is a four-item visual analogue instrument that addresses the following areas of the therapeutic
alliance: (a) Client rating of the relationship between the clinical staff member and the client;
(b) Client rating of whether their clinical staff member is utilizing the session to work on the
goals and topics the client wants to work on; (c) Client rating of whether the clinical staff
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member’s approach or method is a good fit for them; (d) Client rating of the overall session
the day seen. Participants are asked to rate each of the 4 items presented on a scale of 0 to 10.
All four scales are then added together for an overall score. Based on a total possible score of
40, any score lower than 36 overall, or less than 9 on any scale, could be a source of concern
in regards to therapeutic alliance and is discussed with the client by the clinical staff member.
Scores under 36 are suggestive of having an issue with the therapeutic alliance.
The first scale is the “Relationship” scale and is measured with 1 = I did not feel
heard, understood, and respected; and 10 = I felt heard, understood, and respected. The
second scale is the “Goals and Topic” scale and is measured with 1 = We did not work on or
talk about what I wanted to work on and talk about; and 10 = We worked on and talked about
what I wanted to work on and talk about. The third scale is the “Approach or Method” scale
and is measured with 1 = the therapist’s approach is not a good fit for me; and 10 = the
therapist’s approach is a good fit for me. The fourth and final scale is the “Overall” scale and
is measured with 1 being = There was something missing in the session today; and 10 =
Overall, today’s session was right for me. The lower the score, the less TA indicated; an
overall score of 36 is the threshold of measuring good TA. The agency used for this study
collects these data for every client and for every individual and group session and maintains
the scores in the client’s electronic chart.
Scoring is to be done in front of the client using a centimeter ruler. Each of the four
visual analogue scales is 10cm, so the score for each of the four visual analogue scales is the
measurement length on the ruler (e.g. 3.3 cm = score of 3.3) with 10 being the highest score
for each scale. You simply write the score in the right margin (based on the mark on the
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ruler), and then add the four scores for the overall score. The overall score is rounded up or
down to a whole number. The total possible score is 40. One limitation is that although a
ruler is used to score the SRS and all staff are trained to use the SRS and score it, there is no
way to know for fact that each clinical staff member did use a ruler or if they eyeballed the
score, as the researcher was not there at the time of administration. Therefore, there is no way
to verify that the scoring is consistent from one clinical staff member to the next. The
concern in consistency comes to light in noting that the SRS does not have a numbered scale,
thus a mark close to the middle between two numbers could be the lower number for one
staff member and raised for another staff member (e.g., close to 3.5 could look more like 3.4
to one clinician and 3.6 to another). This could affect the validity and reliability of the
instrument.
The Revised Helping Alliance Questionnaire (HAQ-II) (Luborsky, Barber, Siqueland,
Johnson, Najavits, Frank, & Daley, 1996) was used to evaluate the psychometric properties
of the SRS in a study by Duncan, Miller, Sparks, Claud, Reynolds, Brown and Johnson
(2003). The coefficient alpha for all administrations (N = 420) was .88. “The coefficient
alpha for the SRS compared favorably with that reported for the HAQ II (.90)” (Duncan,
Miller, Sparks, Claud, Reynolds, Brown & Johnson, 2003, p. #). The fact that the 4-item
measure correlated such a high reliability with the 19 items from the HAQ-II is reported by
Duncan, Miller, Sparks, Claud, Reynolds, Brown, and Johnson to suggest evidence that the
four items of the SRS consisted of a good global measure of TA.
The SRS concurrent validity was computed using Pearson product-moment
correlations between the SRS total score and HAQ II total score. The data from a sample of
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420 paired administrations for the 70 participants produced a correlation between the two
measures of .48, which suggest evidence of concurrent validity for the SRS (Duncan, Miller,
Sparks, Claud, Reynolds, Brown & Johnson, 2003). Correlations between each of the 4
individual SRS items and the HAQ II score were within a range of .39 to .44. These
correlations provided evidence of the degree to which the SRS items are assessing the same
construct as the HAQ-II.
The relationship to outcome of treatment was also evaluated to ensure it could predict
outcome indications similar to other established alliance measures, in order to validate its
construct validity. Outcome indicators in relation to this study were also important as
retention and compliance in methadone treatment are the outcome indicators for this study. A
random sample of 100 clients was utilized to compare to the outcome from the Outcome
Rating Scale (Duncan & Miller, 2000). The results revealed a correlation of .29 between the
second or third session of the SRS scores and the final session ORS scores. Duncan, Miller,
Reynolds, Sparks, Claud, Brown, and Johnson (2004) stated that studies have found the SRS
to be a valid measure of the therapeutic relationship in regards to retention in and outcome of
treatment.
Data Analysis
This study involved collecting information on the report of therapeutic alliance as
measured from the client’s perception and the relationship to methadone maintenance
treatment retention and compliance. Calculations were made for both descriptive and
inferential statistics using SPSS 21. The study employed four types of analysis. In order to
provide descriptions of the sample, descriptive statistics were used to gain information on
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gender, age, race, marital status, employment status, and dosing levels. The means and
standard deviations of the SRS and measures of client compliance scores were gathered.
Also, mode, median, and range was used to measure for any overall patterns in the sample.
All variables were assessed for normalcy. In addition to histograms and boxplots, measures
of skewness and kurtosis were used to evaluate whether the sample collected meets normalcy
assumptions.
To assess the relationship and test the hypotheses between SRS scores and
compliance scores and retention measure, appropriate correlation coefficients and regression
analyses was computed. After all the scores were analyzed logistic regression was applied to
the variables of Hypothesis 1, 2 and 3. This was utilized because the data was reviewed as
categorical for both the dependent and independent variables. This researcher was looking at
whether there was a positive TA reported (yes or no), the client was retained > or equal to 12
months, and the client was treatment compliant in area of drug screenings and attendance to
scheduled sessions (individual and group). Lastly, to identify the existence of any specific
patterns or relationships between the aforementioned demographic variables and survey or
test scores, additional group tests such as chi-square, t-tests, and/or analysis of variance were
used to examine for any significant differences among the scores and demographics.
Research Questions and Hypotheses
The research questions that drove the analysis were stated in Chapter 1 as:
Research Question 1: Does positive therapeutic alliance as measured by the Session
Rating Scale (SRS) predict retention (as measured by length of stay in treatment) among
patients receiving methadone maintenance treatment?
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Ha1: Report of positive therapeutic alliance as measured by a raw score of 36 or above
on the SRS will predict treatment retention measured as 12 or more months in MMT.
H01: Report of positive therapeutic alliance as measured by a raw score of 36 or
above on the SRS will not predict treatment retention measured as 12 or more months in
MMT.
Research Question 2: Does positive therapeutic alliance as measured by the Session
Rating Scale (SRS) predict compliance (as measured by attendance to scheduled
appointments) among patients receiving methadone maintenance treatment?
Ha2: Report of positive therapeutic alliance as measured as a raw score of 36 or above
on the SRS will predict treatment compliance as measured by client’s attendance record
showing three or less non-excused missed appointments over the preceding 12 months of
MMT treatment.
H02: Report of positive therapeutic alliance as measured as a raw score of 36 or
above on the SRS will not predict treatment compliance as measured by client’s attendance
record showing three or less nonexcused missed appointments over the preceding 12 months
of MMT treatment.
Research Question 3: Does positive therapeutic alliance as measured by the Session
Rating Scale (SRS) predict compliance (as measured by results of drug testing analysis)
among patients receiving methadone maintenance treatment?
Ha3: Report of positive therapeutic alliance as measured as a raw score of 36 or above
on the SRS will predict treatment compliance as measured by client’s drug test results
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showing fewer than three positive illicit drug results over the preceding 12 months of MMT
treatment.
H03: Report of positive therapeutic alliance as measured as a raw score of 36 or above
on the SRS will not predict treatment compliance as measured by client’s drug test results
showing fewer than three positive illicit drug results over the preceding 12 months of MMT
treatment.
Threats to Validity
With any research, there is some potential threats to validity. This section will discuss
possible threats to this research project specifically. The degree a study establishes a causeand-effect relationship between the treatment and the observed outcome is internal validity
(Slack & Draugalis, 2001; p 2173). It is possible that there could be potential for an internal
effect that could not be controlled for in this study called an interaction of temporal and
group composition effects. Although archival data was used for this study, many of the
participants had been involved in MMT for 1 year or more and there could have been
changes in their behavior that are related to pre-existing differences among the participants
(e.g. pre-existing differences such as age, marital status, geographical location of treatment,
employment and etc.) that could obscure the effects of therapeutic alliance. Demographic
characteristics also can impact the study, there were differences among the sample
participants that could have influenced the building of TA such as gender, age, marital status,
co-occurring diagnosis and etc. In this study it is possible that one or more of these
demographic characteristics may not have equally been accounted for. One other threat noted
to internal validity is potential of selective sample attrition. In MMT some of the participants
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discharged due to voluntary reasons and some discharged involuntarily such as in situations
of noncompliance.

Another threat to validity of a study is related to external validity issues one such
possibility is the reactive or interaction effect of testing. One concern with external validity is
how representative the sample is to the population as a whole. Once potential concern in this
area is that the sample was comprised of opioid addicts only in Arizona. While there may be
many generalizations in regards to opioid addicts in general, this study did not look at
demographic influences in regards to geographic location that may influence the forming of
therapeutic alliance. Another potential issue Interaction effect of testing, this occurs when
there is pretesting. In the case of this study the SRS is presented to clients every session,
which could have a possible effect of pretesting such as overtime the clients may become so
familiar with the questions that they don’t answer them how they really feel but according to
a learned response (e.g. selecting all one score every session). Another possible threat to
external validity is interaction effects of selection biases and the experimental treatment.
While there was no direct experimental treatment with this study, there were a number of
cases that were eliminated from the study due to not having all the necessary information to
be included in the study. There is no way to account for the potential effects that those
members of the population’s data may have had on the outcomes of this study.

One final concern in psychological study is construct validity which is the extent that
an
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instrument measures what it purports, to be measuring. Duncan, Miller, Sparks,
Claud, Reynolds, Brown & Johnson, (2003) identified that the SRS was developed as an
“ultra-brief” alliance scale to be utilized by mental health staff session to session. It may be
notable that the measures used to compare and determine psychometric properties of the SRS
had been “designed for research and theoretical purposes” and thus may not have taken into
account the difference utilizing the SRS session to session.
Summary
This chapter covered the processes and methods that this researcher undertook to
examine the differences between the report of client and the clinical staff member’s
perception of therapeutic alliance, and whether the perception of TA by either the client or
clinical staff member may have a significant effect on treatment compliance results and/or
retention outcomes.
This quantitative study examined individuals who have been receiving MMT from
various MMT outpatient clinics ran by the agency used for this study in Arizona. The data
associated with TA was gathered by using data from the SRS, treatment compliance was
determined by reports on drug screening results and reported attendance to scheduled
individual and group sessions held in electronic records by the agency used for this study.
In Chapter Four, the results of study are presented to determine if differences exist
between the report of client’s and the clinical staff’s perceptions of therapeutic alliance, and
whether the perception of therapeutic alliance by either the client or clinical staff member is
related to treatment compliance and/or retention outcomes.

66
Chapter 4: Results
Introduction
I investigated the relationship between TA and the variables of retention and
compliance in methadone maintenance treatment. Significant amounts of research relate to
the role and influence of TA in mental health psychotherapy with adult clients, which is a
critical component influencing outcomes and retention within counseling in the mental health
field. There is comparatively little known about the relationship between alliance and therapy
outcome with regard to the influence of retention and compliance with methadone
maintenance treatment.
I used research questions to examine the effect of TA (measured using the Session
Rating Scale) on MMT retention and compliance (drug screens and session attendance). I
analyzed archival data from 264 clients at four methadone clinics using logistic regression.
With the first research question, I examined whether positive TA, as measured by a raw score
of 36 or above on the SRS to evaluate whether positive reporting of TA can predict retention
among patients receiving MMT. Retention was measured as the client remaining in MMT for
12 or more months. Using the second research question, I examined whether positive
reporting of TA predicted compliance of attendance to scheduled appointments with clients
receiving treatment at MMT. In my second hypothesis, I stated that a report of positive TA
would predict compliance measured by client’s attendance record showing three or less nonexcused missed appointments during the preceding 12 months of MMT. I used the third and
final question of this study to examine whether positive reporting of TA predicted
compliance with maintaining clean negative drug testing analysis among patients receiving
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MMT. In my third hypothesis, I stated that report of positive TA would predict treatment
compliance as measured by client’s negative drug test results showing fewer than three
positive illicit drug results during the preceding 12 months of MMT.
In this chapter, I present the variables, both nominal and scaled, along with
descriptive and inferential statistics pertinent to the hypotheses of study, as outlined in
Chapter 3. The independent variable for analyses was report of TA, measured by SRS scores.
In the first section of this chapter, I describe the data collection process, based on the
research methods reviewed in Chapter 3. In the second section, I present the data analyses
and in the final section, I present the summary and conclusions.

Data Collection
All the data from cases in a database of information for each of the MMT treatment
sites kept by the agency used for this study were reviewed. The data from Session Rating
Scales (See Appendix B) completed by the clients over the last 12 months of their MMT
program was collected from the database maintained by the agency used for this study. This
researcher also received each subject’s demographic information, drug screening results and
treatment sessions attendance records that are held in an electronic database by the agency
used for this study. Any client data with omitted information from the SRS, drug screening
results, session attendance or missing admission/discharge data was omitted from the study.
The evaluation for omitted information was conducted on each randomly selected participant
from the database of the agency used for this study until there was no missing data for any of
the cases in the sample. The agency is a not for profit agency, and clients were evaluated
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from the timeframe of 2010-2014. From the time of approval by the IRB to the retrieval of
the data held in the database by the agency it was four months. This time lapse was so that a
specific report of all the data needed for this study was programmed by the developers to
protect access to other information in client charts not needed for the purpose of this study.
Once the data was received it took 4 more months to sort through all the data to organize it
and an additional two months to complete the analysis of the raw data.
The independent variable for this study was therapeutic alliance which was measured
utilizing SRS scores. In this study, it was noted that based on overall SRS scores (M = 37.3,
SD = 3.12) more than 78% of the sample reported a positive therapeutic alliance (N = 207)
regardless of all other factors, while less than 22% (N = 57) reported not having a therapeutic
alliance.
The predictor variables were compliance with negative drug testing, compliance with
attendance to sessions and retention in treatment. The information for these variables was
obtained through archival records maintained in three databases maintained by the agency
used for this study. The three databases were comprised of the SRS/ORS scores, client
demographics, drug screening reports and attendance records. The data was obtained on
excel spreadsheets from the databases. The first step involved matching up the data from the
three reports (client demographic taken from Health Management System (HMS) and
ensuring that all necessary variables were present (length of service, attendance, and drug
screening results). Participants who had less than two ORS/SRS scores were eliminated
because there could not be an accurate start of service, completion of service and average
score obtained. Also, eliminated from the sample were clients that had less than four reported
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drug screenings in order to be able to look at the results over a course of 1 year. After this
sorting 264 clients were remaining that were able to be matched with all the criteria. The next
step involved adding all the SRS scores which were individually given. The number of SRS
reported scores reviewed in the original raw data for all clients with all data for this study
were N = 4,601. The SRS scores for each client ranged from 3 per client to up to 111 per
client. Each set of scores for the 264 participants was placed on an Excel spreadsheet with
the client’s start of service and end of service to determine number of months a client was
retained in treatment. The total of all SRS scores for each participant (range 3 recorded
scores to 111 recorded scores) was totaled and the overall mean score was calculated for each
participant, and the mean was used to determine overall report of TA during length of
treatment. Therapeutic alliance was coded as positive alliance with SRS score of 36 or above.
The overall sample report on SRS scores (M=37.30, SD=3.12) suggested that there was a
report of TA regardless of any of the other variables (length of treatment, attendance and
drug screen results), as well as any demographic variables or clinic.

The third step involved sorting and coding the drug screening results for each client.
The total number of positive drug screenings was totaled for each client and noted on the
spreadsheet. The range of total number of positive drug screenings ranged from 0 to 18.
Compliance was coded as compliant if there were less than 3 positives in a one-year period.
Out of 264 total participants, 137 participants almost 52% were reported as compliant with
drug screenings compliance criteria (M=3.7, SD 4.09).
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The fourth step involved sorting and coding the attendance for individual and group
appointments. Attendance was only able to be followed if it was placed in the HMS system.
The total of missed appointments was tallied and noted on the spreadsheet. The range of
reported missed appointments was from 0 missed to 68 missed appointments. Compliance
was coded as compliant if there 3 or less missed sessions in a one-year period. Out of 264
participants only 67 participants or about 25% were reported as compliant. The overall
missed appointments rate was much higher than 3 in one year (M=12.99, SD=11.21).

The next step was totaling and coding treatment retention. The length of service
months was determined by totaling the number of months between the admission dates to the
discharge date for discharged clients. The length of service months for current clients was
based on the number of months between the admission date and the date of the report.
Retention criteria was based on length of service of 12 months or more. Out of 264
participants 217 participants (82%) were retained and 47 participants (18%) were not
retained for 1 year or more. The overall length of treatment for this sample was just over 19
months (M = 19.30, SD = 8.171).
The final step before analysis was conducted was to take the data and convert it to
categorical data to become dichotomous variables, in preparation for the logistic regression
analysis. At this point TA was coded either yes = 2 (overall scores of 36 and greater) or no =
1 (<36). Retention was coded as retained for 1 year or more as yes = 2 and retained for <1
year as no = 1. Compliance for drug screening was coded as compliance –drug screening < 3
positive drug screenings yes = 2 and non-compliant with drug screenings >2 no = 1. And
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finally, compliance – session attendance was coded as 3 or less missed sessions yes = 2 and
non-compliant to session attendance as no = 1.6
Sample Description
After verifying all data, the following Descriptive Analysis describes the
demographics of the 264 remaining participants that comprised the sample for this study. The
sample was composed of 54.5 % (N = 144) males and 45.5 % (N = 120) females, age of 21 to
77 (M = 39.47, SD = 12.34). Almost 68% of the participants were Caucasian (N = 179), the
remaining distribution of ethnicity included 23% Hispanic (N = 60), 6 % Black (N = 16), 3%
American Indian (N = 7), and less than 1% each Asian or Pacific (N = 1) or other or not
provided (N = 1). About 48% (N = 126) of the participants were single, 22.3% (N = 59) were
married, 4.5% (N = 12) were separated, 13.3% (N = 35) were divorced, 2.7% (N = 7) were
widowed and 9.5% (N = 25) did not report their marital status. The largest percentage of the
participants came from an urban clinic that for confidentiality purposes will be known as
clinic A, 37.5 % (N = 99) which was to be expected as it was located in a major city, the
remainder of the distribution was 16.7% (N = 44) from clinic B, 15.9% (N = 42) from clinic
C and 29.9% (N = 79) from clinic D. Client treatment status was coded and was fairly
equally divided with current clients making up 52% (N = 136) and discharged clients making
up 48% (N = 128) of the sample. In regards to a co-occurring mental health diagnosis 89.4%
(N = 236) had no other mental health diagnosis while those remaining 10.6% (N = 28) were
reported with an Axis I non-substance related mental health diagnosis.
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Table 1
Frequency and Percentage Breakdown of Demographic Variables (N= 264)
Descriptives
%
M

Variable

N

Clinic
A
B
C
D

99
44
42
79

37.5%
16.7%
15.9%
29.9%

Gender
Male
Female

144
120

54.5%
45.5%

Age Group
18-30 years old
31-55 years old
56-70 years old
71 and over
Employment Status
Volunteer
Unpaid rehab
Homemaker
Student
Retired
Disabled
Fulltime Employed
Part-time Employed
Unemployed
Unknown or did not report
Race
other
African American
Caucasian
Hispanic
Native American
Marital Status
Single
Married
Separated
Divorced
Widowed
Did not report status

7
42
65
8

SD

1.45

.5

39.47

12.3

2.29
(Table

1.653
Continues)

5.7%
34.4%
53.3%
6.6%

1
1
3
8
4
32
50
34
128
1

.4%
.4 %
1.1 %
3.0%
1.5%
12.1%
18.9%
12.9%
48.5%
.4%

2
16
179
60
7

.8%
6.1%
67.8%
22.7%
2.7%

126
59
12
35
7
25

47.7%
22.3%
4.5%
13.3%
2.7%
9.5%
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Occurrence of an Axis I mental health
diagnosis
Axis I mental health diagnosis
No other mental health diagnosis
Treatment status
Currently enrolled
Discharged

28
236

10.6%
89.4%
.327
1.12

136
128

51.5%
48.5%
.501
1.52

The proposed sample size for this study was established by using Cohen’s table
(Cohen, 1992, p. 158) to estimate the number of participants needed. For one predictor of
therapeutic alliance a sample size of at least 76 participants per group of clients would be
required to ensure adequate power to detect medium treatment effects with an alpha set at .05
and a power of 80. This study had 264 participants, thus meeting the criteria for power.
In comparing representation of the sample of the current study to the
population as a whole there were some similarities and differences found. The National
Survey of Substance Abuse Treatment Services (N-SSATS) (2012) identified that there were
537,676 clients in 2012 that made up 43.1% of the population receiving MMT, that also had
a diagnosed co-occurring disorder. This study found only 10.6% of the sample to have a
diagnosed co-occurring disorder. Rosenblum et al. (2007) conducted a multi-state survey to
determine the prevalence of prescription opioid abuse. The study included 5663 opioid
dependent clients from 72 methadone maintenance treatment programs across the U.S. The
Rosenblum et al. study identified that a mean age of 35, while the current study the mean age
was 39.47. Further the Rosenblum study found 36.6% of their sample included women, while
the current study included 45.5% women. In regards to race, Rosenblum reported 73.1% of
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the sample was white, 13.0% black and 11.7% Hispanic. Similarly, the current study
included 67.8 % of the sample was white, but only found 6.1% to identify as black and there
was a larger representation of Hispanic 22.7%. The difference in the Hispanic representation
maybe related to the proximity of Arizona to the border of Mexico. Both studies evidenced
the majority of the sample from counties with over 1 million population 59.3 % in the
Rosenblum study and 37.5% in the current study. In regards to employment there was a
difference in the representation of those employed, 46.7% employed in the Rosenblum study
while in the current study only 31.8% of sample was employed.
Results
Three separate logistic regressions were conducted to test each of the three
hypotheses. Logistic regression was deemed appropriate for this analysis because the
independent variable was dichotomous (yes/no), as were the dependent variables. The
independent variable was therapeutic alliance. The dependent variables were also
dichotomous: retention, compliance –drug screening, and compliance – session attendance.
Results for Hypothesis 1
The first logistic regression was performed to ascertain whether TA predicted
retention for 1 year or more in methadone maintenance treatment. The model was not
statistically significant χ2 (1) = .508, p = .476, suggesting that TA is not a significant
predictor of the likelihood of retention (see Table 2). The model explained less than 1% of
the variance in retention (Nagelkerke R2 = .003). The null hypothesis was retained.
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Results for Hypothesis 2
The second logistic regression was performed to ascertain whether therapeutic
alliance predicted compliance in drug screening. The model was not statistically significant
2

χ (1) = .223, p = .636, suggesting that TA is not a significant predictor of the likelihood of
retention (see Table 2). The model explained less than 1% of the variance in drug screening
2

compliance (Nagelkerke R = .001. The null hypothesis was retained.
Results for Hypothesis 3
The third logistic regression was performed to ascertain whether therapeutic alliance
2

predicted compliance in session attendance. The model was not statistically significant m (1)
= .026, p = .872, suggesting that TA is not a significant predictor of the likelihood of
retention (see Table 2). The model explained less than 1% of the variance in compliance in
2

session attendance (Nagelkerke R < .001. The null hypothesis was retained.
Table 2

Summary of Logistic Regression Using Therapeutic Alliance to Predict Retention and Compliance (n = 264)

Retention

Alliance
χ

2

df
*p < .05.

Compliance: Session
attendance

Compliance: Drug screening

B

SE B

eB

B

SE B

eB

B

SE B

eB

0.17

0.374

1.31

0.141

0.299

1.152

0.055

0.346

1.057

0.508

476

0.223

p = .636

0.873

p = .872

1

1

1
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Summary
This chapter reported the results of three hypotheses addressing factors that examined
effect on clients completing methadone maintenance treatment. Data for 264 participants was
analyzed for the purpose of this study. For Hypothesis 1, the model was not effective in
reporting those cases that would be retained in methadone maintenance treatment.
Hypothesis 2 purported that clients reporting a strong TA would be compliant with scheduled
sessions. The model was not effective in reporting those cases that would meet the
attendance criteria. The third hypothesis, regarding whether positive reporting of TA would
correctly predict the successful compliance to the drug screening criteria was also not
supported.
The interpretation of findings, discussion regarding the significance of the study and
the limitations of the study, social change implications, recommendations for further study
and a summary are discussed in Chapter 5.
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Chapter 5: Summary, Conclusion, and Recommendations
Introduction
The use of opioids continues to increase and approximately 8 million people
worldwide abuse opioids (Van der Burgh, 1999). Opioid abuse costs include medical
associated costs, criminal activity costs, and emotional costs to families of the substance
abuser and are a significant burden on society (Ghate et al., 2010; White et al., 2005;
SAMHSA, 2013; Birnbaum et al., 2004). MMT is an effective treatment for opioid addiction
with regard to improving both the life of the opioid-addicted individual and society (Teoh
Bing Fei, Yee, Hussain Bin Habil, & Danaee, 2016). As explained in Chapter 1, opioid abuse
affects society with burdens related to health costs of HIV infections, criminal behavior, and
deaths from overdose. Studies have identified that retention in MMT is a major factor in
reduction of risks and successful outcomes (Kayman et al., 2006; Magura et al., 1998).
Studies have shown that treatment dropout has been an issue with MMT (Gossop et
al., 2002; Reisinger et al., 2009; Simpson & Sells, 1982). Therefore, maintaining retention in
MMT is an important factor for society and the opioid-addicted individual. A poor
therapeutic connection (therapeutic alliance) has been found to affect success of treatment,
especially with regard to retention and compliance (Palmer et al., 2009; Joe et al., 2007;
Kelly et al., 2010; Meir et al., 2006; Duncan & Miller, 2008). My underlying approach in this
study was that finding the link between improving the effectiveness of MMT while not
adding to the costs of the treatment could assist in continuing this treatment modality that has
been shown to be effective. Developing TA would not necessarily increase program costs as
significantly as developing social supports such as vocational training, more intensive
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treatment, costs of criminal justice structure, or other options. Building therapeutic rapport
can be taught through in-service trainings or other means. Therefore, it appeared that
improving TA may be one of the least expensive ways to improve retention and compliance
in MMT, which prompted the current study.
Prior research suggests that a better report of therapeutic alliance would suggest better
treatment outcomes (Zhang et al., 2009; Joe et al., 2007; Meier et al., 2005). As I detailed in
Chapter 2, several studies have identified that the relationship between the client and the
clinical staff on working on mutual goals (therapeutic alliance) affects treatment outcomes
and participation in treatment (Orlinsky et al., 1994; Duncan et al., 2006; Martin et al., 2000).
The reports of the overall sample from the SRS scores suggested that regardless of
any of the variables, of the 264 participants, 78% of participants (N = 207) reported a positive
TA regardless of length of treatment, attendance, and drug screen results; therefore, in the
current study, TA was reported regardless of treatment outcomes. The sample for this study
included individuals who had been discharged owing to noncompliance issues, and according
to prior research, it would have suggested that those clients should have reported lower levels
of TA, but this was not the case. Various theories explain the difference from the actual
outcome and what was expected. I will discuss this in further detail in the Limitations
section. Due to the finding of high levels of positive TA regardless of the variable, further
research should attempt to narrow the reasoning for the SRS scoring suggesting TA.
I examined the possibility that a positively reported therapeutic alliance could predict
retention and compliance in methadone maintenance treatment. The positive social change
implications meant for this study were to allow therapists to integrate strategies into
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treatment that would promote building therapeutic alliance, thus improving the retention and
compliance with MMT.
The purpose of this chapter is to discuss the results of the study reported in Chapter 4,
including how these findings relate to other researchers’ results, implications of these
findings for practice and social change, strengths and limitations, and recommendations for
future research. The organization of this chapter is: (a) interpretation of the findings, (b)
limitations of the study, (c) implications for social change, (d) recommendations for future
research, and (e) conclusions noting how the findings fit with existing literature.
Interpretation of the Findings
Research Question 1
The first regression analysis assessed whether the report of positive therapeutic
alliance could help predict retention of 12 months or more in Methadone Maintenance
Treatment (MMT). The research found that therapeutic alliance did not significantly
associated with retention. The results of this sample showed the average length of treatment
was about 19 months and the overall sample reported a positive therapeutic alliance
regardless of any of the other variables. The information that there was a report of therapeutic
alliance regardless of any other influence in this study offered some speculation and more
questions for future research that will be discussed in the discussion and future research
section.
While this study did not support a relationship between therapeutic alliance (TA) and
retention the role of therapeutic alliance in the outcome of drug treatment, has been very well
researched and found to be an important factor (Safran & Muran, 2000). Studies by Simpson
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(1982, 1997) found that the quality of therapeutic relationship significantly influences length
of stay. Meier, Donmall, McElduff, Barrowclough & Heller (2006) identified that
therapeutic alliance ratings were among the strongest predictor of dropout in drug abuse
treatment. Nathan & Gorman (2015, p. 744) identified that therapeutic “alliance early in
treatment is associated with a longer length of stay in treatment”. Davila Torres (2010)
identified that the staff-patient relationship (therapeutic alliance) was an important factor that
promotes the retention in the MMT. The findings of this study did not support therapeutic
alliance as a predictor for methadone maintenance treatment outcomes related to retention,
and compliance.
It may be difficult to speculate why there was no significant association found
between therapeutic alliance and retention in this study. However, it is important to note that
the report of negative or positive therapeutic alliance result also does not clearly guarantee
that treatment will be not be successfully completed therefore, further research should
continue to work to determine the variables that most effectively relate to successful MMT
outcomes. Results of this study suggested that therapeutic alliance was reported as positive
regardless to whether retention was maintained or not and could have been impacted by
numerous influences that were unable to be controlled for in this study. Suggestions for
future research to evaluate those influences will be discussed more in the section on
limitations and suggestions for future research.
Research Questions 2 and 3
The second and third regression analysis assessed whether the report of positive
therapeutic alliance could help predict compliance in Methadone Maintenance Treatment
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(MMT). Research question 2 specifically addressed compliance in regards to attendance for
scheduled sessions and question 3 compliance in regards to adherence with illicit drug use
policies. In this study the report of positive therapeutic alliance did not assist with predicting
compliance with attendance or adherence with illicit drug use policy.
Again, while this study did not support a relationship between therapeutic alliance
(TA) and compliance to attendance with scheduled counseling and case management
sessions the role of therapeutic alliance in attendance has been researched and supported in
other studies. Better attendance was associated with better outcomes in substance abuse
treatment (Hubbard, Craddock, Flynn, Anderson, & Etheridge, 1997; Simpson, 1981; Zhang,
Friedmann, & Gerstein, 2003). Therapeutic alliance has been identified as a predictor for
attendance (Fiorentine, Nakashima, & Anglin, 1999; Simpson, Joe & Brown, 1997). Joe et al.
(1999) determined that a strong correlation existed between the ratings of therapeutic alliance
and drug treatment compliance outcomes, including illicit drug use and session attendance. A
meta-analysis of 24 studies, found there was a reliable and consistent relationship between
the working alliance with the counselor and the client and therapy outcomes (Horvath &
Symonds, 1991). Meier, Donmall, McElduff, Barrowclough & Heller (2006) identified that
the report of early alliance appeared to be a consistent predictor of engagement.
Based on this study it appears there may be other variables that would influence
whether someone makes it to their schedule sessions regularly. If clients are not committed to
the need for further therapy and their belief is they just need the methadone, this could
explain the lack of attendance to counseling and case management sessions. The methadone
takes care of the withdraw symptoms, which is what clients may want, there could be a
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disconnect on the need for therapy. If someone is experiencing pain, they are more likely to
justify taking time out of their life to go see the doctor in order to get rid of the pain. It is may
be harder for individuals to justify going to see the doctor for well visits. This finding will be
discussed in more detail in the discussion and suggestions for future research section.
The final component of compliance selected for this study was compliance in
avoiding illicit drug use which is the main goal of MMT. The final logistic regression was
performed to evaluate the effect of reported therapeutic alliance on the likelihood that
participants would be compliant to drug use policy. This study identified that once again the
model was not effective in predicting compliance with regard to drug screenings.
Part of the benefit of MMT is the contribution of prevention of infectious disease
spread through IV drug use (Ward et al., 1999; Reisinger et al., 2009; Krambeer et al., 2001).
But in a study conducted of cohort study of 764 HIV-1-infected patients it was found that
forty-four percent of active drug users failed to utilize highly active antiretroviral therapy
(HAART) (Lucas, Cheever, Chaisson, Moore, 2001). This finding may suggest that
compliance with avoidance of illicit drug use is an important factor in receiving treatment for
infectious diseases. There was limited research related directly to whether therapeutic
alliance contributes directly to reduction in illicit drug use, the majority of the research
focused on treatment outcomes overall.
Although the results of this study did not yield a significant finding that therapeutic
alliance had a strong influence on successful MMT outcomes, there may have been other
influences such as anyone or combination of demographic characteristics. The real
implications of this study should indicate that there is need for further research.
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Limitations
The current study’s intention was to add to the body of knowledge on therapeutic
alliance and improving methadone maintenance treatment retention and compliance by
examining archival data. There were many limitations associated with this study. Shultz,
Hoffman & Reiter-Palmon (2005) identified that researchers experience several
methodological and statistical issues when using archival data. Further Shultz, Hoffman &
Reiter-Palmon identified some of the downfalls of utilizing archival data and there were a
couple that also could have been an influence with the current study such as; completeness of
documentation, inability to detect errors in the data. The data used in this study was archival
in type and thus the method with which the data was collected originally was a significant
concern for consistency and accuracy. Further, the archival data collection sample from the
agency used for this study was not collected under controlled circumstances.
A potential limitation of this study and utilizing the Session Rating Scale relates to
the law of diminishing returns. The law of diminishing returns originally was utilized by
economists to explain that at a particular point, additional input produces less output (Mold,
Hamm & McCarthy, 2010) and it was identified that the law may also offer insight into
situations related to clinical medicine. The theory may relate to the current study in which the
more you experience something, the less effective it becomes. The client’s in this study were
administered the SRS at every session, initially the client’s may have put effort into the
scoring, but over time being exposed to the SRS numerous times the client’s may have been
influenced decreased motivation in scoring the SRS. A study was conducted in order to
examine the short-term effects on treatment alliance and patient satisfaction from using the
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PCOMS scales (ORS and SRS) in out-patient mental health treatment, compared to treatment
without using feedback scales (Rise, Eriksen, Grimstad & Steinsbekk (2012), which after six
weeks showed no statistical difference on alliance and satisfaction.
The way the SRS/ORS was presented may have varied from one clinical staff
member to another. There exist inabilities to ensure that every survey question with each
client was scored precisely in the same manner. Also there was an assumption that clinical
staff made adjustments as necessary for cultural and other related factors, such as a need for
an interpreter.
In reviewing the data, although not factored into analysis it was noted that there was a
difference between clinics. As discussed in the study there were a total of 4 different MMT
clinics that data was collected from. One clinic was in a major city with a census of over 1.5
million (37.5%) in 2014 (U.S. Census Bureau, 2014), the other three were located in towns
with populations ranging from 39,000 to 70,000, and those three locations were located in
rural areas. Comparing this in relation to other studies such as Rosenblum et al. (2007),
where the study evidenced the majority of the sample from counties with over 1 million
population 59.3 %. There could be a difference in the reporting of TA between rural and
urban MMT clinics and in outcomes of treatment. One last major difference between the
clinic’s is that the one located in the major city was also the oldest clinic having opened in
1994. The other three clinics were acquired in 2012. Perhaps due to the length of time that
the oldest clinic has existed has offered the staff there an opportunity to build more
experience on developing TA. It also could be that just the length of time the clients had
worked with the staff had influenced the strength of TA over time. There may also be other
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influences related to being located in an urban area as opposed to a rural area in regards to
availability to get to the clinic, due to limited public transportation options. It may be
beneficial to study the variables of rural vs. urban influence on TA, compliance and
retention. One other issue with the data may have been the fact that it was categorized from
the original data. If the data had been left in its original form, there may have been more
precise results that could have affected the outcomes.
Another possible limitation is related to the nature of the clients being served. An
assumption had to be that the participants were able to form some type of TA with clinical
staff through direct contact. One concern related to TA development was that the population
of substance abusers often exhibit characteristics related to Personality Disorders, which in
itself suggests potential issues with development of TA such as malingering or the need to
present oneself in a positive light. Those with personality disorders are may exhibit
significant issues in the formation of a therapeutic alliance (Wright & Davis, 1994; Bender,
2005). Another aspect of substance abuse is there is often a co-occurring diagnosis,
SAMHSA (2015) reported that in 2014 there were approximately 7.9 million adults with cooccurring disorders. The current study did not analyze the effect of the mental health disorder
on the report of TA. Future studies may want to analyze the effect of Anti-Social
characteristics and mental health symptoms on the report of therapeutic alliance.
Another significant limitation is within the measurement bias related to the selfreporting nature of the study from the clients’ perspective, clinical staff’s perspective and the
influence of the client and clinical staff desiring to present themselves in a favorable manner.
As stated in Chapter 4, the sample utilized for this study included individuals that had been
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discharged due to noncompliance issues, and according to prior research it would have
suggested that those clients should have reported lower levels of TA, but this was not the
case. It may be that clients report TA because they have a desire to be perceived in a positive
light (social desirability). A study was conducted examining socially desirable responding
(SDR), (the tendency for people to present a favorable image of themselves) on
questionnaires (van de Mortel, 2008). The study by van de Mortel identified out of fourteen
thousand two hundred and seventy-five studies using Questionnaire‑based research, 43%
found that social desirability response influenced their results (van de Mortel, 2008, p 42).
The clients know that the therapist will see the results of the SRS and their desire to be
perceived in a favorable image may influence their scores on the SRS. Other options that
may influence clients scoring of the SRS could be fear being treated differently if they give
negative responses. Duncan et al. (2003) identified, “Clients tend to score all alliance
measures highly”, but did not give possible reasoning. It is also possible that the SRS is
presented in a manner that leads the client to believe it is a “grading scale” for the clinician,
and thus they may not want to negatively impact the clinician’s job. Another thought is that
the clients are not invested into the meaning and use of the SRS and thus scoring what they
think the clinical staff desires to hear. It also may be that the SRS is not an appropriate
assessment of TA in this set of conditions. It may be that the receiving of the methadone
treatment itself is the factor acknowledged by the client as the needed treatment and the
receiving of that treatment is all that the client needed to report therapeutic alliance. Finally,
since methadone treatment is the one factor keeping them from abusing opioids, the client
may have a fear that if they report negatively that there could be a repercussion or retaliation
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that could affect their continued services. There was no research identified that addressed the
above mentioned possible influences on reporting of TA, therefore it may be beneficial to
conduct further research addressing such issues.
The National Substance Abuse Treatment System (2003) estimated that 151,882
clients are in outpatient methadone treatment for opioid addiction this study only collected
data on individuals that were enrolled in an outpatient MMT program in Arizona, it did not
include those receiving treatment in a higher treatment level of care such as inpatient or in a
different environment (e.g. a PCP office) which may have yielded different results. Another
limitation related to the selection bias, it is the geographic influence as the data was collected
from clinics only in Arizona so cannot be generalized to the population as a whole.
Discussion and Recommendations for Future Research
Although the results of this study did not yield a significant finding that
therapeutic alliance had a strong influence on successful MMT outcomes, it may have been
influenced by one of the previously mentioned limitations. Regardless of outcomes of the
treatment and other factors, the majority of participants endorsed positive TA. It may be
beneficial to clarify the definition of what TA is and what it is not to clients and clinicians.
Bedi, Davis and Williams (2005) point out that often the clients and clinical staff do not see
that qualities and the strength of TA the same. This study viewed the TA as occurring within
the one to one therapy or the group counseling sessions, it may be possible that the client
viewed it from the perspective of the ability to receive the methadone they see as necessary
as the treatment. With this scenario, the clients are receiving the treatment (methadone) that
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manages their ailment (withdrawal symptoms) and thus regardless of what occurs within an
individual or group session they see the overall picture in a positive light.
It is also possible that the client may also desire to be seen personally in a positive
light and have concerns that if they report negativity on the SRS that they will be personally
viewed negatively. Words that clinical staff report such as; refusal of treatment, in denial,
resistive to treatment, may sound intimidating to a client who knows the clinical staff can
take their treatment away from them. Reisinger et al., (2009) examined reasons clients
discharge from MMT prematurely and found one reason identified as conflicts with staff. If
this is a concern of the client, they may feel the need to report TA positively so they are not
viewed as refusing or resistive. Perhaps in regards to methadone treatment specifically,
further research may be beneficial in the area of whether clients feel they can be honest about
their feelings.
Another factor that stood out across the study regardless of outcomes was retention.
The majority of the participants in this study were retained for a minimum of 1 year,
regardless of whether they were compliant with treatment or not. Interestingly, there did not
appear to be any consistency in consequences when clients were not compliant with
scheduled sessions or with drug screenings. It could be the perceived lack of response to
noncompliance influenced the report of therapeutic alliance. If there was limited to no
addressing of noncompliance the client could have viewed that as the clinical staff supporting
them and their behavior, thus the client may have viewed it as a positive therapeutic alliance.
Therefore, another suggestion for future research consideration would be conducting this
study with controls on response to noncompliance to one group and not to the other group,
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which may offer some needed information into evaluating whether the retention improved
outcomes or whether possible boundary setting of noncompliance could influence outcomes.
Furthermore, the client may lack understanding of how to score the SRS, or there
could be a lack of urgency or importance in regards to how the data from the SRS is used.
Perhaps the high scoring of TA with this study has to do with the clinical staff’s training and
then their presentation of the information. The results of the report of TA could be related to
the SRS itself and by repeating the study with another assessment, the outcomes may be
different. The psychometric properties of the SRS suggest high internal consistency
compared to the HAQ and high test-retest reliability in comparison to the HAQ II (Duncan et
al., 2003), but as previously stated in this study the used to establish psychometric properties
of the SRS were developed for research as opposed to session to session evaluation. One
concern in consistency comes to light in noting that the SRS does not have a numbered scale.
It is supposed to be measured with a ruler but there is no way to verify if each clinical staff
member did use a ruler or if the measured data was estimated. The effect of estimation could
be that a mark close to the middle between two numbers could be the lower number for one
staff member and raised higher for another staff member (e.g. a mark between 3 and 4 could
look closer to 3 for one staff and closer to 4 for another staff). If clinical staff have concerns
regarding the instrument scores being used to grade their performance in any form, they also
may be more likely to report the marks as higher than lower. There did not appear to be any
research addressing the consistency of clinician to clinician scoring and this may be an area
for further research in relation to appropriateness of the SRS with this population.
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It was interesting that TA was reported whether or not a client was compliant or not,
and whether they were retained or not. The original premise of this study was that if a client
reported TA that they would also be compliant in attending sessions and with drug screening.
Overall, this study suggested that a large portion of clients were not compliant with drug
screenings or attendance to sessions and yet they were still retained in treatment for an
average of 1.5 years and overall reported TA. It may be important to go back and define what
are the important components of MMT outcomes in order to attain the goals of the treatment.
One final thought for future study suggestions is that the outcomes of this study did
not address whether an individual remained abstinent after discharge from methadone
treatment. It may be beneficial for future studies to conduct a longitudinal type study on
maintained abstinence and the benefits of methadone treatment in relation to abstinence.
Social Change Implications
The American Society of Addiction Medicine (ASAM) reported in its Opioid
Addiction 2016 Facts & Figures that drug overdose is the leading cause of accidental death in
the US and Opioid addiction and opioid related deaths were the highest for all drugs. ASAM
reported opioid use disorder figures at 1.9 million for opioid based pain relievers and 586,000
related to heroin use disorders in 2014 (ASAM, 2016). These figures affect a large portion of
the population of the U.S., whether someone they know someone who has opioid dependence
or through indirect cost such as rising medical costs or working in the medical field or law
enforcement. Research has shown that the length of stay in treatment is one of the most
consistent predictors positive treatment outcomes (Simpson, Joe, Broome, Hiller, Knight &
Rowan-Szal, 1997; Simpson, Brown & Joe, 1997; Joe et al., 2009). Therefore, this study’s
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hope was to find a potentially low cost way to improve MMT retention and compliance
through improving therapeutic alliance.
Some important implications that emanated from the current study's findings related
to research methodology. Results from the current study adds to the knowledge base
of quantitative research specifically in relation to therapeutic alliance measurement
instruments related to this population. This study was undertaken due to the significant gap
of research related to successful retention in MMT and MMT outcomes. Research related to
therapeutic alliance identified report of positive therapeutic alliance exhibits evidence of
positive treatment outcomes within mental health. The majority of the research on
therapeutic alliance identified in Chapter 2 was related to mental health. There was limited
research related to therapeutic alliance and substance abuse outcomes, as stated previously in
this study the field of substance abuse has been slower than other fields in embracing
research on the effect of therapeutic alliance on treatment outcomes (Ritter, Bowden,
Murray, Ross, Greeley, & Pead, 2002). In relation to methadone maintenance treatment there
was almost no research related directly to therapeutic alliance and MMT outcomes.
Closing Summary
Although the results of this study did not represent a finding that TA was a strong
influence on successful MMT outcomes, the study results did offer some interesting avenues
for further researcher suggesting the need for more research.
The premise of this study was that the therapeutic alliance occurred during individual
sessions and group sessions, as that is the only place where it is measured. Assessing with an
instrument usually occurs during group or individual sessions and therefore a positive or
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negative report was considered directly related to the clinical staff member in that session. It
was also assumed that individual and/or group sessions were an essential part of the
methadone treatment process. In talking to various staff members at two of the clinics it was
identified by staff that a small percentage of clients actually receive individual therapy and
may attend an average of 1 group per week. Perhaps more focus on therapy and less focus on
compliance could be another way to improve overall methadone maintenance treatment
outcomes.
Many people in the U.S. are impacted in some manner by opioid dependence, so we
must do all we can to ensure that those who are receiving methadone maintenance treatment
are retained in service and compliant with treatment.
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Appendix A: Data Use Agreement
This Data Use Agreement (“Agreement”), effective as of August 15, 2014 (“Effective
Date”), is entered into by and between Teresa Fresquez (“Data Recipient”) and The agency used for
this study (“Data Provider”). The purpose of this Agreement is to provide the Data Recipient with
access to a Limited Data Set (“LDS”) for use in research in accord with laws and regulations of
the governing bodies associated with the Data Provider, Data Recipient, and Data Recipient’s
educational program. In the case of a discrepancy among laws, the agreement shall follow
whichever law is more strict.
1. Definitions. Due to the study’s affiliation with Laureate, a USA-based company, unless
otherwise specified in this Agreement, all capitalized terms used in this Agreement not
otherwise defined have the meaning established for purposes of the USA “HIPAA
Regulations” and/or “FERPA Regulations” codified in the United States Code of Federal
Regulations, as amended from time to time.
2. Preparation of the LDS. Data Provider shall prepare and furnish to Data Recipient a LDS in
accord with any applicable laws and regulations of the governing bodies associated with the
Data Provider, Data Recipient, and Data Recipient’s educational program.
3. Data Fields in the LDS. No direct identifiers such as names may be included in the Limited
Data Set (LDS). In preparing the LDS, Data Provider shall include the data fields specified
as follows, which are the minimum necessary to accomplish the research: Session Rating
Scale scores, gender, age, race, gender, marital status, employment status, dosing level, drug
reports and attendance to individual and group information.
4. Responsibilities of Data Recipient. Data Recipient agrees to:
a.

Use or disclose the LDS only as permitted by this Agreement or as required by law;

b.

Use appropriate safeguards to prevent use or disclosure of the LDS other than as
permitted by this Agreement or required by law;

c.

Report to Data Provider any use or disclosure of the LDS of which it becomes aware
that is not permitted by this Agreement or required by law;

d.

Require any of its subcontractors or agents that receive or have access to the LDS to
agree to the same restrictions and conditions on the use and/or disclosure of the LDS
that apply to Data Recipient under this Agreement; and

e.

Not use the information in the LDS to identify or contact the individuals who are data
subjects.
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5. Permitted Uses and Disclosures of the LDS. Data Recipient may use and/or disclose the LDS for
its Research activities only.
6. Term and Termination.
a.

Term. The term of this Agreement shall commence as of the Effective Date and shall
continue for so long as Data Recipient retains the LDS, unless sooner terminated as
set forth in this Agreement.

b.

Termination by Data Recipient. Data Recipient may terminate this agreement at any
time by notifying the Data Provider and returning or destroying the LDS.

c.

Termination by Data Provider. Data Provider may terminate this agreement at any
time by providing thirty (30) days prior written notice to Data Recipient.

d.

For Breach. Data Provider shall provide written notice to Data Recipient within ten
(10) days of any determination that Data Recipient has breached a material term of
this Agreement. Data Provider shall afford Data Recipient an opportunity to cure said
alleged material breach upon mutually agreeable terms. Failure to agree on mutually
agreeable terms for cure within thirty (30) days shall be grounds for the immediate
termination of this Agreement by Data Provider.

e.

Effect of Termination. Sections 1, 4, 5, 6(e) and 7 of this Agreement shall survive any
termination of this Agreement under subsections c or d.

7. Miscellaneous.
a.

Change in Law. The parties agree to negotiate in good faith to amend this Agreement
to comport with changes in federal law that materially alter either or both parties’
obligations under this Agreement. Provided however, that if the parties are unable to
agree to mutually acceptable amendment(s) by the compliance date of the change in
applicable law or regulations, either Party may terminate this Agreement as provided
in section 6.

b.

Construction of Terms. The terms of this Agreement shall be construed to give effect
to applicable federal interpretative guidance regarding the HIPAA Regulations.

c.

No Third Party Beneficiaries. Nothing in this Agreement shall confer upon any
person other than the parties and their respective successors or assigns, any rights,
remedies, obligations, or liabilities whatsoever.

d.

Counterparts. This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and
the same instrument.

121
e.

Headings. The headings and other captions in this Agreement are for convenience and
reference only and shall not be used in interpreting, construing or enforcing any of the
provisions of this Agreement.
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Appendix B Session Rating Scale

Session Rating Scale (SRS V.3.0)
Name ________________________Age (Yrs):____
ID# _________________________ Sex: M / F
Session # ____ Date: ________________________
Please rate today’s session by placing a mark on the line nearest to the description that best
fits your experience.

Relationship
I did not feel
heard, understood,
and respected.

I felt heard,

I------------------------------------------------------------------------I understood, and
respected.

Goals and Topics
We did not
work on or talk about
what I wanted to work
on and talk about.

We worked on
and talked about what
I wanted to work on
and talk about.

I-----------------------------------------------------------------------I

Approach or Method
The therapist’s
approach is not a good
fit for me.

The therapist’s

I------------------------------------------------------------------------Iapproach is a good fit
for me.

Overall
There was
something missing in
the session today.

Overall,

I------------------------------------------------------------------------Itoday’s session was
right for me.

Institute for the Study of Therapeutic Change
_______________________________________
www.talkingcure.com
© 2002, Scott D. Miller, Barry L. Duncan, & Lynn Johnson
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Appendix C Session Rating Scale Agreement

IMPORTANT!
By downloading this file you have indicated your complete agreement
and willingness to abide by the terms of the ORS, SRS, CORS, CSRS,

1. Licensee:
By signing
below, you are
hereby
licensed by
YCORS/SRS, GSRS, GCSRS, LASS and Oral Versions Binding License
PCOMS
International,
Agreement
Inc (hereafter
PCOMS) to
use the ORS, SRS, CORS, CSRS, YCORS/SRS,GSRS, GCSRS, LASS and Oral Versions (hereafter the measures) for your individual use only. Any
use of these measures by an agency, group practice, clinic, managed behavioral care organization, or government requires separate application for a
group license and payment of appropriate fees. Click here to apply for or obtain information regarding a group license.
2. ORS, SRS, CORS, CSRS, YCORS/SRS, GSRS, GCSRS, LASS and Oral Versions : The measures mean any and all paper and pencil or
electronic versions of the outcome and process measures, progress and process tracking systems, outcome and process screening, and outcome and
process prognosis measurement.
3. License: Subject to the terms and conditions of this agreement, PCOMS grants to the licensee a license to use the measures in connection with the
licensee’s bona fide health care practice. The administration and scoring manual, and any and all electronic versions or scoring products associated
with the measures may NOT be copied, transmitted, or distributed by the licensee. Paper and pencil versions of the measures may be copied for use in
connection with the licensee’s bona fide health care practice.
4. Modifications: The licensee may NOT modify, translate into other languages, change the context, wording, or organization of the measures or
create any derivative work based on them. The licensee may put the measures into other written, non-electronic, non-computerized, non-automated
formats provided that the content, wording, or organization are not modified or changed. The licensee may modify the item line length so that each
prints out 10 cm.
5. Copies, Notices, and Credits: Any and all copies of the measures made by the licensee must include the copyright notice, trademarks, and other
notices and credits on measures. Such notices may not be deleted, omitted, obscured or changed by the licensee. Since you are obtaining the license for
individual use only, you may NOT distribute copies of the measures.
6. Use, distribution, and Changes: The measures may only be used and distributed by the licensee in connection with licensee’s bona fide health care
practice and may not be used or distributed for any other purpose.
7. Responsibility: Before using or relying on the measures, it is the responsibility of the licensee to read and understand the ORS and SRS
Administration and Scoring Manual. It is also the responsibility of the licensee to ascertain their suitability for any and all uses made by the licensee.
The measures are not diagnostic tools sand should not be used as such. The measures are not substitutes for an independent professional evaluation.
Any and all reliance on the measures by the licensee is at the licensee’s sole risk and is the licensee’s sole responsibility. Licensee indemnifies PCOMS
and it’s officers, directors, employees, representatives, and authors of the measures against, and hold them harmless from, any and all claims and law
suits arising from or relating to any use of or reliance on the measures and related products provided by PCOMS. This obligation to indemnify and hold
harmless includes a promise to pay any and all judgments, damages, attorney’s fees, costs and expenses arising from any such claim or lawsuit.
8. Disclaimer: Licensee accepts the measures and associated products “as is” without any warranty of any kind. PCOMS disclaims any and all implied
warranties, including implied warranties of merchantability, fitness for a particular purpose, and non-infringement. PCOMS does not warrant that the
measures are without error or defect. PCOMS shall not be liable for any consequential, indirect, special, incidental or punitive damages. The aggregate
liability of PCOMS for any and all causes of action (including those based on contract, warranty, tort, negligence, strict liability, fraud, malpractice, or
otherwise) shall not exceed the fee paid by the licensee to PCOMS. This license agreement, and sections 7 and 8 in particular, define a mutually agreed
upon allocation of risk. The fee reflects such allocation of risk.
9. Construction: The language used in this agreement is the language chosen by the parties to express their mutual intent, and no rule of strict
construction shall be applied against any party.
10. Entire agreement: This agreement is the entire agreement of the parties relating to the measures.
11. Governing Law: This agreement is made and entered into in the State of Florida and shall be governed by the laws of the State of Florida. In the
event of any litigation or arbitration between the parties, such litigation or arbitration shall be conducted in Florida and the parties hereby agree and
submit to such jurisdiction and venue.
12. Modification: This agreement may not be modified or amended.
13. Transferability: This agreement may not be transferred, bartered, loaned, assigned, leased, or sold by the licensee.
14. Violations: Violations of any provision or stipulation of this agreement will result in immediate revocation of this license. Punitive damages may
be assessed.
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Appendix D Key Codes

Original
Marital status
coding Key

Employment Status coding
Key

Single
Married

1
2

Separated

Ethnicity
coding
Key

8
14

Caucasian
Hispanic

1
2

3

Unemployed
Volunteer
Unpaid
Rehab
activity

17

3

Divorced

4

Homemaker

19

Widowed

5

Student

20

unknown or not
reported

6

Retired
Disabled

21
22

black
American
Indian or
Alaskan
Native
Asian or
Pacific
Islander
Other or
not
provided

Incarcerated
Fulltime
employed
Part-time
employed
Work
adjustment
Transitional
employment
Unknown,
not reported

23

Recoded
Marital Status
(see page 77)
Married=(married
or separated)
Single= (single,
divorced or
widowed)

24
25
26
27
6

4

5

6
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Key codes continued
Retention
Retention under 1 year=No not retained=coded as 1
Retained for 1 year or more=Yes retained=coded as 2
Therapeutic Alliance Report
Therapeutic Alliance not reported=SRS score under 36=1
Therapeutic Alliance reported=SRS score 36 or above=2
Compliance with drug testing
Not compliant=3 or more positive drug test= 1
Compliant=Less than 3 positive drug test=2
Compliance with attendance to scheduled sessions
Noncompliant=more than 3 missed sessions=1
Compliant=3 or less missed sessions=2

